Drug_ID Indication_name Indication_icd Indication_phase ReferenceID DG01485 Small-cell lung cancer [ICD-11: 2C25] Investigative REF00004824 DG00194 Hepatitis virus infection [ICD-11: 1E50-1E51] Approved REF00004633 DG01826 Bacillary dysentery [ICD-11: 1A02] Approved REF00004586 DG01670 Non-small-cell lung cancer [ICD-11: 2C25] Approved REF00004571 DG01544 Ewing sarcoma [ICD-11: 2B52] . REF00004571 DG01617 Small-cell lung cancer [ICD-11: 2C25] Approved REF00004552 DG01617 Triple negative breast cancer [ICD-11: 2C60-2C6Y] Approved REF00004552 DG01600 Hepatitis C virus infection [ICD-11: 1E50-1E51] Investigative REF00004552 DG01582 Malignant mesothelioma [ICD-11: 2C26] Phase 1 REF00004548 DG01582 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00004548 DG01582 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00004548 DG01546 Nasopharyngeal carcinoma [ICD-11: 2B6B] Phase 2 REF00004546 DG01546 Rectal adenocarcinoma [ICD-11: 2B92] Phase 2 REF00004546 DG01486 Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 REF00004539 DG01489 Diabetic complication [ICD-11: 5A2Y] Investigative REF00004539 DG01576 Breast cancer [ICD-11: 2C60] Phase 3 REF00004535 DG01576 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 REF00004535 DG01819 Hypothalamic hypogonadism [ICD-11: 5A60-5A61] Approved REF00004534 DG01597 Cholangiocarcinoma [ICD-11: 2C12] Phase 2 REF00004532 DG01597 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00004532 DG01462 Throat irritation [ICD-11: CA0Z] Investigative REF00004525 DG01533 Breast cancer [ICD-11: 2C60] Phase 2 REF00004523 DG01478 Convulsion [ICD-11: 8A61-8A6Z] Phase 3 REF00004522 DG01493 Bacterial infection [ICD-11: 1A00-1C4Z] Investigative REF00004519 DG01644 Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 REF00004518 DG01818 Central nervous system disease [ICD-11: 8A04-8D87] Approved REF00004515 DG01594 Gastric adenocarcinoma [ICD-11: 2B72] Phase 2/3 REF00004505 DG01594 HER2-positive breast cancer [ICD-11: 2C60-2C6Y] Phase 2/3 REF00004505 DG01618 Non-small-cell lung cancer [ICD-11: 2C25] Phase 1 REF00004501 DG01618 Non-small-cell lung cancer [ICD-11: 2C25] Phase 1 REF00004501 DG01618 Anaplastic large cell lymphoma [ICD-11: 2A90] Phase 1 REF00004501 DG01618 Non-small-cell lung cancer [ICD-11: 2C25] Phase 1 REF00004501 DG01471 Heart arrhythmia [ICD-11: BC65] Approved REF00004496 DG01783 Diabetic complication [ICD-11: 5A2Y] Approved REF00004479 DG01783 Obesity [ICD-11: 5B81] Approved REF00004479 DG01783 Type-2 diabetes [ICD-11: 5A11] Approved REF00004479 DG01531 Cystic fibrosis [ICD-11: CA25] Phase 3 REF00004475 DG01605 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical REF00004474 DG01494 Multi-drug resistant tuberculosis [ICD-11: MG50-MG52] Phase 2 REF00004467 DG01669 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 REF00004467 DG01669 Multiple myeloma [ICD-11: 2A83] Phase 3 REF00004467 DG01494 Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2 REF00004467 DG01831 Breast cancer [ICD-11: 2C60] Phase 1 REF00004457 DG01794 Discovery agent [ICD-11: N.A.] Investigative REF00004452 DG01551 Hepatitis C virus infection [ICD-11: 1E50-1E51] Phase 1 REF00004451 DG01551 Hepatitis C virus infection [ICD-11: 1E50-1E51] Phase 1 REF00004451 DG01532 Melanoma [ICD-11: 2C30] Phase 3 REF00004450 DG01532 Melanoma [ICD-11: 2C30] Phase 3 REF00004450 DG01532 Ureteral cancer [ICD-11: 2C92] Phase 3 REF00004450 DG01532 Renal cell carcinoma [ICD-11: 2C90] Phase 3 REF00004450 DG01532 Melanoma [ICD-11: 2C30] Phase 3 REF00004450 DG01532 Head and neck cancer [ICD-11: 2D42] Phase 3 REF00004450 DG01532 Breast cancer [ICD-11: 2C60] Phase 3 REF00004450 DG01532 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 REF00004450 DG01611 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative REF00004445 DG01611 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative REF00004445 DG01625 Cholangiocarcinoma [ICD-11: 2C12] Approved REF00004439 DG01625 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00004439 DG01625 Multiple myeloma [ICD-11: 2A83] Approved REF00004439 DG01525 Psoriasis vulgaris [ICD-11: EA90] Investigative REF00004424 DG01775 Insomnia [ICD-11: 7A00] Approved REF00004417 DG01825 Chronic pain [ICD-11: MG30] Approved REF00004416 DG01778 Pain [ICD-11: MG30] Approved REF00004415 DG01770 Rheumatoid arthritis [ICD-11: FA20] Approved REF00004412 DG01496 Renal cell carcinoma [ICD-11: 2C90] Investigative REF00004406 DG01848 Melanoma [ICD-11: 2C30] Approved REF00004405 DG01595 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00004401 DG01595 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00004401 DG01626 Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 REF00004395 DG01624 Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 1 REF00004392 DG01624 Glioma [ICD-11: 2A00] Phase 1 REF00004392 DG01624 Systemic mastocytosis [ICD-11: 2A21] Phase 1 REF00004392 DG01624 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00004392 DG01570 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative REF00004392 DG01488 Bacterial infection [ICD-11: 1A00-1C4Z] Investigative REF00004390 DG01652 Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 1 REF00004389 DG01652 Systemic mastocytosis [ICD-11: 2A21] Phase 1 REF00004389 DG01652 Mast cell leukaemia [ICD-11: 2A21] Phase 1 REF00004389 DG01607 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00004387 DG01631 Non-small-cell lung cancer [ICD-11: 2C25] Patented REF00004384 DG01631 Non-small-cell lung cancer [ICD-11: 2C25] Patented REF00004384 DG01640 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 REF00004375 DG01671 Non-hodgkin lymphoma [ICD-11: 2B33] Phase 1 REF00004373 DG01671 Non-hodgkin lymphoma [ICD-11: 2B33] Phase 1 REF00004373 DG01671 Follicular lymphoma [ICD-11: 2A80] Phase 1 REF00004373 DG01535 Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 REF00004372 DG01529 Hepatitis C virus infection [ICD-11: 1E50-1E51] Phase 2 REF00004367 DG01613 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00004365 DG01613 Breast cancer [ICD-11: 2C60] Approved REF00004365 DG01502 Ovarian cancer [ICD-11: 2C73] Phase 3 REF00004360 DG01515 Skin infection [ICD-11: 1F28-1G0Z] Phase 3 REF00004360 DG01502 Ovarian cancer [ICD-11: 2C73] Phase 3 REF00004360 DG01604 Discovery agent [ICD-11: N.A.] Investigative REF00004359 DG01547 Basal cell carcinoma [ICD-11: 2C32] Phase 2 REF00004355 DG01547 Basal cell nevus syndrome [ICD-11: 2C32] Phase 2 REF00004355 DG01547 Chondrosarcoma [ICD-11: 2B50] Phase 2 REF00004355 DG01566 Thrombosis [ICD-11: DB61-GB90] Phase 3 REF00004348 DG01803 Malaria [ICD-11: 1F40[ Approved REF00004344 DG01550 Essential thrombocythemia [ICD-11: 3B63] Phase 2 REF00004341 DG01550 Essential thrombocythemia [ICD-11: 3B63] Phase 2 REF00004341 DG01550 Vitiligo [ICD-11: ED63] Phase 2 REF00004341 DG01550 Atopic dermatitis [ICD-11: EA80] Phase 2 REF00004341 DG01592 Breast cancer [ICD-11: 2C60] Phase 1 REF00004341 DG01593 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00004341 DG01592 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00004341 DG01592 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00004341 DG01550 Pancreatic cancer [ICD-11: 2C10] Phase 2 REF00004341 DG01550 High-risk myelofibrosis [ICD-11: 2A20] Phase 2 REF00004341 DG01914 Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 REF00004341 DG01781 Pain [ICD-11: MG30] Approved REF00004336 DG01781 Anaesthesia [ICD-11: 8E22] Approved REF00004336 DG01653 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00004332 DG01588 Melanoma [ICD-11: 2C30] Phase 2 REF00004330 DG01588 Melanoma [ICD-11: 2C30] Phase 2 REF00004330 DG01588 Melanoma [ICD-11: 2C30] Phase 2 REF00004330 DG01463 Alzheimer disease [ICD-11: 8A20] Investigative REF00004329 DG01507 Non-small-cell lung cancer [ICD-11: 2C25] Approved REF00004304 DG01639 Cholangiocarcinoma [ICD-11: 2C12] Phase 1 REF00004297 DG01639 Myeloproliferative syndrome [ICD-11: 2A20] Phase 1 REF00004297 DG01639 Bladder cancer [ICD-11: 2C94] Phase 1 REF00004297 DG01517 Breast cancer [ICD-11: 2C60] Phase 3 REF00004294 DG01552 Lymphoma [ICD-11: 2A90- 2A85] Approved REF00004294 DG01484 Malaria [ICD-11: 1F45] Phase 3 REF00004289 DG01467 Diarrhea [ICD-11: DA90] Phase 1 REF00004288 DG01767 Coronary artery disease [ICD-11: BA8Z] Approved REF00004269 DG01779 Parkinson disease [ICD-11: 8A00] Phase 1 REF00004266 DG01521 Melanoma [ICD-11: 2C30] Discontinued in Phase 3 REF00004258 DG01798 Discovery agent [ICD-11: N.A.] Investigative REF00004218 DG01823 Discovery agent [ICD-11: N.A.] Investigative REF00004211 DG01811 Increase blood pressure [ICD-11: BA04] Approved REF00004204 DG01801 Paroxysmal supraventricular tachycardia [ICD-11: BC81] Approved REF00004202 DG01806 Discovery agent [ICD-11: N.A.] Investigative REF00004201 DG01468 Spasm [ICD-11: MB47] Investigative REF00004193 DG01483 Breast cancer [ICD-11: 2C60] Investigative REF00004193 DG01771 Cystitis [ICD-11: GC00] Approved REF00004192 DG01771 Chronic pain [ICD-11: MG30] Approved REF00004192 DG01619 Renal cell carcinoma [ICD-11: 2C90] Phase 1 REF00004183 DG01619 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00004183 DG01567 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00004182 DG01567 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00004182 DG01796 Pancreatic cancer [ICD-11: 2C10] Approved REF00004172 DG01782 Anaesthesia [ICD-11: 8E22] Approved REF00004163 DG01568 Colorectal cancer [ICD-11: 2B91] Phase 1 REF00004162 DG01773 Melasma [ICD-11: ED60] Approved REF00004159 DG01470 Head and body lice [ICD-11: 1G00] Approved REF00004158 DG01469 Psoriasis vulgaris [ICD-11: EA90] Approved REF00004149 DG01536 Myelofibrosis [ICD-11: 2A20] Phase 2 REF00004133 DG01541 Prostate cancer [ICD-11: 2C82] Phase 1/2 REF00004130 DG01541 Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2 REF00004130 DG01541 Colorectal cancer [ICD-11: 2B91] Phase 1/2 REF00004130 DG01541 Breast cancer [ICD-11: 2C60] Phase 1/2 REF00004130 DG01541 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 REF00004130 DG01541 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 REF00004130 DG01556 Triple negative breast cancer [ICD-11: 2C60-2C6Y] Phase 2 REF00004124 DG01556 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00004124 DG01563 Clostridium infection [ICD-11: 1A04] Phase 2 REF00004117 DG01585 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 REF00004109 DG01545 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00004106 DG01537 Breast cancer [ICD-11: 2C60] Approved REF00004101 DG01537 Breast cancer [ICD-11: 2C60] Approved REF00004101 DG01537 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00004101 DG01537 Non-hodgkin lymphoma [ICD-11: 2B33] Approved REF00004101 DG01511 Recurrent glioblastoma [ICD-11: 2A00] Phase 3 REF00004097 DG01511 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 REF00004097 DG01511 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 REF00004097 DG01511 Recurring respiratory infection [ICD-11: CA07-CA4Z] Phase 3 REF00004097 DG01511 Pancreatic cancer [ICD-11: 2C10] Phase 3 REF00004097 DG01511 Hepatocellular carcinoma [ICD-11: 2C12] Phase 3 REF00004097 DG01511 Haematological malignancy [ICD-11: 2B33] Phase 3 REF00004097 DG01511 Gastrointestinal cancer [ICD-11: 2B5B] Phase 3 REF00004097 DG01511 Colorectal cancer [ICD-11: 2B91] Phase 3 REF00004097 DG01511 Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 3 REF00004097 DG01511 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 REF00004097 DG01596 Discovery agent [ICD-11: N.A.] Phase 2 REF00004092 DG01497 Lupus nephritis [ICD-11: 4A40] Phase 3 REF00004079 DG01497 Psoriasis vulgaris [ICD-11: EA90] Phase 3 REF00004079 DG01497 Kidney disease [ICD-11: GC2Z] Phase 3 REF00004079 DG01772 Infectious disease [ICD-11: 1A00-CA43] Approved REF00004075 DG01802 Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 REF00004070 DG01577 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00004069 DG01577 Multiple myeloma [ICD-11: 2A83] Phase 2 REF00004069 DG01577 leukaemia [ICD-11: 2A60-2B33] Phase 2 REF00004069 DG01506 Thyroid cancer [ICD-11: 2D10] Phase 2 REF00004055 DG01506 Melanoma [ICD-11: 2C30] Phase 2 REF00004055 DG01506 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00004055 DG01506 Non-small-cell lung cancer [ICD-11: 2C25] Phase 2 REF00004055 DG01474 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00004036 DG01474 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00004036 DG01474 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00004036 DG01495 Multiple myeloma [ICD-11: 2A83] Terminated REF00004032 DG01495 Breast cancer [ICD-11: 2C60] Terminated REF00004032 DG01520 Non-small-cell lung cancer [ICD-11: 2C25] Phase 2 REF00004022 DG01785 Breast cancer [ICD-11: 2C60] Approved REF00004019 DG01816 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical REF00004017 DG01641 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 REF00004000 DG01612 Discovery agent [ICD-11: N.A.] Phase 2 REF00003999 DG01591 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 REF00003997 DG01540 Primitive neuroectodermal tumour medulloblastoma [ICD-11: 2A00] Phase 3 REF00003996 DG01540 Basal cell carcinoma [ICD-11: 2C32] Phase 3 REF00003996 DG01543 Discovery agent [ICD-11: N.A.] Approved REF00003978 DG01510 Hepatitis C virus infection [ICD-11: 1E50-1E51] Phase 3 REF00003967 DG01522 Non-small-cell lung cancer [ICD-11: 2C25] Investigative REF00003966 DG01505 Parkinson disease [ICD-11: 8A00] Phase 3 REF00003962 DG01505 Parkinson disease [ICD-11: 8A00] Phase 3 REF00003962 DG01538 Prostate cancer [ICD-11: 2C82] Phase 1 REF00003960 DG01538 Pancreatic cancer [ICD-11: 2C10] Phase 1 REF00003960 DG01538 Ovarian cancer [ICD-11: 2C73] Phase 1 REF00003960 DG01538 Ovarian cancer [ICD-11: 2C73] Phase 1 REF00003960 DG01466 Heart block [ICD-11: BC63] Investigative REF00003942 DG01466 Melanoma [ICD-11: 2C30] Investigative REF00003942 DG01465 Bacterial infection [ICD-11: 1A00-1C4Z] Investigative REF00003941 DG01475 Human immunodeficiency virus infection [ICD-11: 1C60-1C62] Approved REF00003940 DG01788 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003934 DG01643 Hepatitis C virus infection [ICD-11: 1E50-1E51] Phase 1/2 REF00003933 DG01549 Thrombocythemia [ICD-11: 3B63] Investigative REF00003930 DG01549 Polycythemia vera [ICD-11: 2A20] Investigative REF00003930 DG01668 Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 REF00003930 DG01548 Endometrial cancer [ICD-11: 2C76] Phase 3 REF00003930 DG01549 Myelofibrosis [ICD-11: 2A20] Investigative REF00003930 DG01638 Discovery agent [ICD-11: N.A.] Phase 3 REF00003918 DG01578 Chronic myelogenous leukaemia [ICD-11: 2A20] Phase 1/2 REF00003916 DG01800 Hypercholesterolaemia [ICD-11: 5C80] Approved REF00003906 DG01534 Myeloproliferative syndrome [ICD-11: 2A20] Discontinued in Phase 1 REF00003902 DG01822 Obesity [ICD-11: 5B81] Approved REF00003899 DG01786 Discovery agent [ICD-11: N.A.] Investigative REF00003899 DG01847 Diabetic complication [ICD-11: 5A2Y] Approved REF00003899 DG01464 Colorectal cancer [ICD-11: 2B91] Approved REF00003898 DG01464 Tumour [ICD-11: 2A00-2F9Z] Approved REF00003898 DG01464 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003898 DG01464 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003898 DG01840 Caerulein stimulated gastric and pancreatic secretion [ICD-11: 5A4Y] Approved REF00003897 DG01840 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003897 DG01824 Discovery agent [ICD-11: N.A.] Investigative REF00003895 DG01472 Bacterial infection [ICD-11: 1A00-1C4Z] Investigative REF00003880 DG01787 Influenza virus infection [ICD-11: 1E30-1E32] Investigative REF00003877 DG01805 Discovery agent [ICD-11: N.A.] Investigative REF00003877 DG01642 Acute myelogenous leukaemia [ICD-11: 2A60] Phase 1 REF00003872 DG01642 Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 REF00003872 DG01789 Piscicide [ICD-11: N.A.] Approved REF00003868 DG01087 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003864 DG01037 Skin disease [ICD-11: EA00-EM0Z] Approved REF00003863 DG01053 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003862 DG00801 Psychomotor agitation [ICD-11: MB23] Approved REF00003861 DG01186 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003860 DG01161 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003859 DG00739 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003858 DG00951 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003857 DG00963 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003856 DG01157 Hypertension [ICD-11: BA00] Approved REF00003855 DG01010 Kidney disease [ICD-11: GC2Z] Approved REF00003854 DG01010 Hyperparathyroidism [ICD-11: 5A51] Approved REF00003854 DG01397 Pain [ICD-11: MG30] Approved REF00003853 DG00667 MRSA infection [ICD-11: 1D01] Approved REF00003850 DG00667 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003850 DG00789 Hypercalcaemia [ICD-11: 5B91] Approved REF00003848 DG01181 Lupus nephritis [ICD-11: 4A40] Approved REF00003826 DG01181 Psoriasis vulgaris [ICD-11: EA90] Approved REF00003826 DG01181 Kidney disease [ICD-11: GC2Z] Approved REF00003826 DG00646 Worm infection [ICD-11: 1F90] Approved REF00003824 DG00628 Breast cancer [ICD-11: 2C60] Investigative REF00003823 DG00628 Multiple myeloma [ICD-11: 2A83] Investigative REF00003823 DG00628 Multiple myeloma [ICD-11: 2A83] Investigative REF00003823 DG01126 Diabetic complication [ICD-11: 5A2Y] Approved REF00003820 DG01117 Open-angle glaucoma [ICD-11: 9C61] Approved REF00003819 DG01254 Non-small-cell lung cancer [ICD-11: 2C25] Approved REF00003816 DG01226 Psoriasis vulgaris [ICD-11: EA90] Approved REF00003815 DG01234 Prostate cancer [ICD-11: 2C82] Approved REF00003811 DG01062 Prostate cancer [ICD-11: 2C82] Approved REF00003811 DG00672 Age-related macular degeneration [ICD-11: 9B75] Approved REF00003809 DG01348 Asthma [ICD-11: CA23] Approved REF00003808 DG01333 Heart transplant rejection [ICD-11: NE84] Approved REF00003805 DG01333 Kidney transplant rejection [ICD-11: NE84] Approved REF00003805 DG00855 Migraine [ICD-11: 8A80] Approved REF00003804 DG00855 Obesity [ICD-11: 5B81] Approved REF00003804 DG01412 Respiratory syncytial virus infection [ICD-11: 1C80] Approved REF00003803 DG00946 Depression [ICD-11: 6A70] Approved REF00003802 DG00890 Hereditary angioedema [ICD-11: 4A00] Approved REF00003801 DG01408 Rheumatoid arthritis [ICD-11: FA20] Approved REF00003800 DG00976 Fungal infection [ICD-11: 1F29-1F2F] Approved REF00003798 DG01155 Malaria [ICD-11: 1F45] Approved REF00003798 DG01033 Skin allergy [ICD-11: 4A80-4A8Z] Approved REF00003797 DG00651 Colorectal cancer [ICD-11: 2B91] Approved REF00003792 DG00651 Lung cancer [ICD-11: 2C25] Approved REF00003792 DG00651 Brain metastases [ICD-11: 2D50-2E2Z] Approved REF00003792 DG00651 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003792 DG00651 Ovarian cancer [ICD-11: 2C73] Approved REF00003792 DG00651 Metastatic colorectal cancer [ICD-11: 2D85] Approved REF00003792 DG00651 Metastatic colorectal cancer [ICD-11: 2D85] Approved REF00003792 DG00674 Impetigo [ICD-11: 1B72] Approved REF00003790 DG01189 Type-2 diabetes [ICD-11: 5A11] Approved REF00003787 DG00994 Parkinson disease [ICD-11: 8A00] Approved REF00003784 DG00800 Nausea [ICD-11: MD90] Approved REF00003779 DG00795 Schizophrenia [ICD-11: 6A20] Approved REF00003779 DG01431 Hodgkin lymphoma [ICD-11: 2B30] Approved REF00003778 DG01152 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003775 DG01377 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003767; REF00003825 DG00802 Allergy [ICD-11: 4A85] Approved REF00003762 DG01274 Migraine [ICD-11: 8A80] Approved REF00003758 DG01217 Migraine [ICD-11: 8A80] Approved REF00003758 DG01369 Hyperprolactinaemia [ICD-11: 5A60-5A61] Approved REF00003758 DG01376 Hyperprolactinaemia [ICD-11: 5A60-5A61] Approved REF00003758 DG01378 Hyperprolactinaemia [ICD-11: 5A60-5A61] Approved REF00003758 DG00929 Cutaneous T-cell lymphoma [ICD-11: 2B00] Investigative REF00003757 DG00929 Actinic keratosis [ICD-11: EK90] Investigative REF00003757 DG00929 Herpes simplex virus infection [ICD-11: 1F00] Investigative REF00003757 DG00928 Skin cancer [ICD-11: 2C30-2C37] Investigative REF00003757 DG00999 Allergic rhinitis [ICD-11: CA08] Approved REF00003756 DG01007 Euvolemic hyponatremia [ICD-11: 5C72] Approved REF00003756 DG01066 Depression [ICD-11: 6A70] Approved REF00003755 DG00863 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003753 DG01160 Nausea [ICD-11: MD90] Approved REF00003748 DG00593 Muscle spasm [ICD-11: MB47] Approved REF00003744 DG00952 Open-angle glaucoma [ICD-11: 9C61] Approved REF00003743 DG01076 Metal intoxication [ICD-11: NE60] Approved REF00003742 DG00842 Discovery agent [ICD-11: N.A.] Approved REF00003742 DG01101 Bacterial infection [ICD-11: 1A00-1C4Z] Investigative REF00003741 DG01223 Complex partial seizure [ICD-11: 8A61-8A6Z] Approved REF00003740 DG01149 Osteoporosis [ICD-11: FB83] Approved REF00003739 DG00985 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003738 DG00748 Castleman's disease [ICD-11: 4B2Y] Approved REF00003737 DG00748 Amyotrophic lateral sclerosis [ICD-11: 8B60] Approved REF00003737 DG00748 Opioid dependence [ICD-11: 6C43] Approved REF00003737 DG00748 Methamphetamine dependence [ICD-11: 6C46] Approved REF00003737 DG00748 Alcohol dependence [ICD-11: 6C40] Approved REF00003737 DG00748 Multiple sclerosis [ICD-11: 8A40] Approved REF00003737 DG01015 Duchenne dystrophy [ICD-11: 8C70] Approved REF00003735 DG00752 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003734 DG01191 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003728 DG01191 Breast cancer [ICD-11: 2C60] Approved REF00003728 DG00981 Prostate cancer [ICD-11: 2C82] Approved REF00003724 DG00981 Prostate cancer [ICD-11: 2C82] Approved REF00003724 DG01418 Hyperuricaemia [ICD-11: 5C55] Approved REF00003720 DG00626 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative REF00003718 DG00627 Discovery agent [ICD-11: N.A.] Investigative REF00003718 DG00575 Perianal crohn disease [ICD-11: DD70] Approved REF00003716 DG00575 Amoebiasis [ICD-11: 1A36] Approved REF00003716 DG00575 Crohn disease [ICD-11: DD70] Approved REF00003716 DG00805 Osteoporosis [ICD-11: FB83] Approved REF00003715 DG00805 Osteoporosis [ICD-11: FB83] Approved REF00003715 DG01314 Essential thrombocythemia [ICD-11: 3B63] Approved REF00003714 DG01314 Thrombocythemia [ICD-11: 3B63] Approved REF00003714 DG00850 Contraception [ICD-11: QA21] Approved REF00003714 DG00984 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003714 DG00923 Asthma [ICD-11: CA23] Approved REF00003713 DG01145 Multi-drug resistant tuberculosis [ICD-11: MG50-MG52] Approved REF00003711 DG00693 Throat irritation [ICD-11: CA0Z] Approved REF00003709 DG00844 Hypertension [ICD-11: BA00] Approved REF00003706 DG00724 Functional bowel syndrome [ICD-11: DD91] Approved REF00003704 DG01003 Hyperuricaemia [ICD-11: 5C55] Approved REF00003703 DG00620 Essential thrombocythemia [ICD-11: 3B63] Approved REF00003699 DG00620 Essential thrombocythemia [ICD-11: 3B63] Approved REF00003699 DG00620 Vitiligo [ICD-11: ED63] Approved REF00003699 DG00620 Atopic dermatitis [ICD-11: EA80] Approved REF00003699 DG00620 Pancreatic cancer [ICD-11: 2C10] Approved REF00003699 DG00620 High-risk myelofibrosis [ICD-11: 2A20] Approved REF00003699 DG01406 Triple negative breast cancer [ICD-11: 2C60-2C6Y] Approved REF00003698 DG01406 Small-cell lung cancer [ICD-11: 2C25] Approved REF00003698 DG01406 Renal cell carcinoma [ICD-11: 2C90] Approved REF00003698 DG01406 Recurrent glioblastoma [ICD-11: 2A00] Approved REF00003698 DG01406 Prostate cancer [ICD-11: 2C82] Approved REF00003698 DG01406 Pancreatic cancer [ICD-11: 2C10] Approved REF00003698 DG01406 Ovarian cancer [ICD-11: 2C73] Approved REF00003698 DG01406 Multiple myeloma [ICD-11: 2A83] Approved REF00003698 DG01406 Malignant pleural mesothelioma [ICD-11: 2C26] Approved REF00003698 DG01406 Gastric adenocarcinoma [ICD-11: 2B72] Approved REF00003698 DG01406 Gastric adenocarcinoma [ICD-11: 2B72] Approved REF00003698 DG01406 Follicular lymphoma [ICD-11: 2A80] Approved REF00003698 DG01406 Esophageal cancer [ICD-11: 2B70] Approved REF00003698 DG01406 Diffuse large B-cell lymphoma [ICD-11: 2A81] Approved REF00003698 DG01406 Chronic myelogenous leukaemia [ICD-11: 2A20] Approved REF00003698 DG01406 Central nervous system lymphoma [ICD-11: 2B33] Approved REF00003698 DG01406 Non-small-cell lung cancer [ICD-11: 2C25] Approved REF00003698 DG01406 Melanoma [ICD-11: 2C30] Approved REF00003698 DG01243 Breast cancer [ICD-11: 2C60] Approved REF00003695 DG00924 Cushing disease [ICD-11: 5A70] Approved REF00003693 DG01405 Head and neck cancer [ICD-11: 2D42] Approved REF00003692 DG00898 Respiratory distress syndrome [ICD-11: CB00] Approved REF00003689 DG01154 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003686 DG01011 Liver disease [ICD-11: DB90-DB9Z] Approved REF00003683 DG01166 Renal cell carcinoma [ICD-11: 2C90] Approved REF00003682 DG01256 Prostate cancer [ICD-11: 2C82] Registered REF00003681 DG00571 Primary Immunodeficiency [ICD-11: 4A01] Approved REF00003680 DG00922 Hyperprolactinaemia [ICD-11: 5A60-5A61] Approved REF00003679 DG01104 Peptic ulcer [ICD-11: DA61] Approved REF00003678 DG01370 Menopause symptom [ICD-11: GA30] Approved REF00003677 DG00843 Nephropathic cystinosis [ICD-11: 5C60] Approved REF00003676 DG01242 Inflammatory arthritis [ICD-11: FA2Z] Approved REF00003674 DG00725 Lymphatic filariasis [ICD-11: 1F66] Approved REF00003673 DG00653 Worm infection [ICD-11: 1F90] Approved REF00003673 DG00650 Hereditary hemorrhagic telangiectasia [ICD-11: LA90] Approved REF00003672 DG01321 Angina pectoris [ICD-11: BA40] Approved REF00003671 DG00546 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative REF00003670 DG00546 Ovarian cancer [ICD-11: 2C73] Investigative REF00003670 DG01068 Pruritus [ICD-11: EC90] Approved REF00003668 DG01450 Meningitis [ICD-11: 1D01] Approved REF00003667 DG01180 Acute coronary syndrome [ICD-11: BA41-BA43] Approved REF00003665 DG01112 Psoriasis vulgaris [ICD-11: EA90] Approved REF00003663 DG01241 Arthropathy [ICD-11: FA11-FA5Z] Approved REF00003660 DG00624 Bacterial infection [ICD-11: 1A00-1C4Z] Investigative REF00003659 DG01429 Bone marrow transplantation [ICD-11: QB63] Approved REF00003658 DG01067 Anaesthesia [ICD-11: 8E22] Approved REF00003656 DG00727 Meniere disease [ICD-11: AB31] Approved REF00003655 DG00761 Pain [ICD-11: MG30] Approved REF00003652 DG00761 Osteoarthritis [ICD-11: FA00-FA05] Approved REF00003652 DG00761 Migraine [ICD-11: 8A80] Approved REF00003652 DG00761 Musculoskeletal pain [ICD-11: MG30] Approved REF00003652 DG00761 Pain [ICD-11: MG30] Approved REF00003652 DG01301 Tourette syndrome [ICD-11: 8A05] Approved REF00003651 DG01301 Tardive dyskinesia [ICD-11: 8A02] Approved REF00003651 DG01299 Tardive dyskinesia [ICD-11: 8A02] Approved REF00003651 DG01299 Huntington disease [ICD-11: 8A01] Approved REF00003651 DG01300 Hyperkinetic movement disorder [ICD-11: 6B60] Approved REF00003651 DG01300 Huntington disease [ICD-11: 8A01] Approved REF00003651 DG00988 Alcohol dependence [ICD-11: 6C40] Approved REF00003649 DG01173 Hyperthermia [ICD-11: MG26] Approved REF00003646 DG00868 Attention deficit hyperactivity disorder [ICD-11: 6A05] Approved REF00003643 DG00868 Pain [ICD-11: MG30] Approved REF00003643 DG01153 High blood pressure [ICD-11: BA00] Approved REF00003642 DG00695 Alzheimer disease [ICD-11: 8A20] Approved REF00003641 DG00888 Human immunodeficiency virus infection [ICD-11: 1C60-1C62] Approved REF00003637 DG01102 Bronchitis [ICD-11: CA20] Approved REF00003636 DG01143 Pain [ICD-11: MG30] Approved REF00003632 DG01119 Insomnia [ICD-11: 7A00] Approved REF00003631 DG01092 Parkinson disease [ICD-11: 8A00] Approved REF00003631 DG00762 Postoperative inflammation [ICD-11: 1A00-CA43] Approved REF00003630 DG01213 Chronic obstructive pulmonary disease [ICD-11: CA22] Approved REF00003628 DG01291 Small-cell lung cancer [ICD-11: 2C25] Approved REF00003627 DG01291 Triple negative breast cancer [ICD-11: 2C60-2C6Y] Approved REF00003627 DG01232 Pediatric growth disorder [ICD-11: FB86] Approved REF00003622 DG00587 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003611 DG00956 Malaria [ICD-11: 1F45] Approved REF00003609 DG00956 Malaria [ICD-11: 1F45] Approved REF00003609 DG00931 Acute supraventricular tachycardia [ICD-11: BC81] Approved REF00003603 DG00788 Schistosomiasis [ICD-11: 1F86] Approved REF00003598 DG00637 Epilepsy [ICD-11: 8A60] Approved REF00003593 DG00637 Epilepsy [ICD-11: 8A60] Approved REF00003593 DG00641 Epilepsy [ICD-11: 8A60] Approved REF00003593 DG00641 Seizure disorder [ICD-11: 8A61-8A6Z] Approved REF00003593 DG00637 Type-1 diabetes [ICD-11: 5A10] Approved REF00003593 DG00638 Epilepsy [ICD-11: 8A60] Approved REF00003593 DG00641 Epilepsy [ICD-11: 8A60] Approved REF00003593 DG00641 Alcohol dependence [ICD-11: 6C40] Approved REF00003593 DG00640 Epilepsy [ICD-11: 8A60] Approved REF00003593 DG00595 Seizure disorder [ICD-11: 8A61-8A6Z] Approved REF00003593 DG00639 Epilepsy [ICD-11: 8A60] Approved REF00003593 DG00639 Bipolar disorder [ICD-11: 6A60] Approved REF00003593 DG00638 Alcohol dependence [ICD-11: 6C40] Approved REF00003593 DG00640 Fibromyalgia [ICD-11: MG30] Approved REF00003593 DG00637 Gastric adenocarcinoma [ICD-11: 2B72] Approved REF00003593 DG00659 Erectile dysfunction [ICD-11: HA00-HA01] Approved REF00003590 DG00661 Visceral leishmaniasis [ICD-11: 1F54] Approved REF00003589 DG00661 Leishmaniasis [ICD-11: 1F54] Approved REF00003589 DG01022 Parasitic infection [ICD-11: 1D0Y-1G2Z] Approved REF00003581 DG01121 Pain [ICD-11: MG30] Approved REF00003578 DG01121 Pain [ICD-11: MG30] Approved REF00003578 DG01121 Back pain [ICD-11: ME84] Approved REF00003578 DG01014 Breast cancer [ICD-11: 2C60] Approved REF00003573 DG01236 HIV-associated lipodystrophy [ICD-11: 1C60-1C62] Approved REF00003567 DG01263 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003564 DG01263 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003564 DG01263 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003564 DG00648 Chronic lymphocytic leukaemia [ICD-11: 2A82] Approved REF00003563 DG00648 Chronic lymphocytic leukaemia [ICD-11: 2A82] Approved REF00003563 DG01388 Melanoma [ICD-11: 2C30] Approved REF00003560 DG00880 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003559 DG00764 Major depressive disorder [ICD-11: 6A70-6A7Z] Approved REF00003557 DG01255 Overactive bladder [ICD-11: GC50] Approved REF00003554 DG00735 Glaucoma/ocular hypertension [ICD-11: 9C61] Approved REF00003553 DG00735 Duodenal ulcer [ICD-11: DA63] Approved REF00003553 DG00901 Chagas disease [ICD-11: 1F53] Approved REF00003551 DG00901 Trypanosomiasis [ICD-11: 1D51-1F53] Approved REF00003551 DG01021 Virus infection [ICD-11: 1A24-1D9Z] Approved REF00003550 DG01021 Osteoporosis [ICD-11: FB83] Approved REF00003550 DG01107 Ocular allergy [ICD-11: 4A80-4A8Z] Approved REF00003547 DG01375 Deep vein thrombosis [ICD-11: BD71] Approved REF00003544 DG01375 Pulmonary embolism [ICD-11: BB00] Approved REF00003544 DG01375 Deep vein thrombosis [ICD-11: BD71] Approved REF00003544 DG01069 Worm infection [ICD-11: 1F90] Approved REF00003541 DG00867 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003539 DG01046 Gonorrheal vaginitis [ICD-11: GA02] Approved REF00003538 DG00553 Tenosynovial giant cell tumour [ICD-11: 2F7B] Approved REF00003537 DG00553 Tenosynovial giant cell tumour [ICD-11: 2F7B] Approved REF00003537 DG00553 Pigmented villonodular synovitis [ICD-11: FA2Z] Approved REF00003537 DG00553 Neurofibromatosis type 1 [ICD-11: LD2D] Approved REF00003537 DG00553 Alzheimer disease [ICD-11: 8A20] Approved REF00003537 DG01096 Worm infection [ICD-11: 1F90] Approved REF00003533 DG01041 Hypercholesterolaemia [ICD-11: 5C80] Approved REF00003530 DG01270 Non-hodgkin lymphoma [ICD-11: 2B33] Approved REF00003529 DG01270 Non-hodgkin lymphoma [ICD-11: 2B33] Approved REF00003529 DG01271 Small lymphocytic lymphoma [ICD-11: 2A82] Approved REF00003529 DG01271 Follicular lymphoma [ICD-11: 2A80] Approved REF00003529 DG01270 Follicular lymphoma [ICD-11: 2A80] Approved REF00003529 DG01271 Arthritis [ICD-11: FA20] Approved REF00003529 DG01002 Virus infection [ICD-11: 1A24-1D9Z] Approved REF00003525 DG01020 Respiratory tract infection [ICD-11: CA07-CA4Z] Approved REF00003520 DG01195 Pulmonary arterial hypertension [ICD-11: BB01] Approved REF00003518 DG00652 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative REF00003515 DG00652 Multiple myeloma [ICD-11: 2A83] Investigative REF00003515 DG00652 leukaemia [ICD-11: 2A60-2B33] Investigative REF00003515 DG01401 T-cell leukaemia [ICD-11: 2A90] Approved REF00003514 DG01401 Cutaneous T-cell lymphoma [ICD-11: 2B00] Approved REF00003514 DG01401 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003514 DG01401 Sezary syndrome [ICD-11: 2B02] Approved REF00003514 DG01401 Sezary syndrome [ICD-11: 2B02] Approved REF00003514 DG01401 Mycosis fungoides [ICD-11: 2B01] Approved REF00003514 DG01401 Mycosis fungoides [ICD-11: 2B01] Approved REF00003514 DG01268 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003512 DG01268 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003512 DG01268 Chronic lymphocytic leukaemia [ICD-11: 2A82] Approved REF00003512 DG01004 Systemic sclerosis [ICD-11: 4A42] Approved REF00003511 DG01105 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003510 DG01310 Virus infection [ICD-11: 1A24-1D9Z] Approved REF00003509 DG00549 Thrombosis [ICD-11: DB61-GB90] Approved REF00003504 DG00548 Pain [ICD-11: MG30] Approved REF00003504 DG00548 Cardiovascular disease [ICD-11: BA00-BE2Z] Approved REF00003504 DG00548 Myocardial infarction [ICD-11: BA41] Approved REF00003504 DG01060 Pseudomonas infection [ICD-11: 1B92] Approved REF00003503 DG00876 Head and body lice [ICD-11: 1G00] Approved REF00003501 DG00982 Thrombosis [ICD-11: DB61-GB90] Approved REF00003500 DG00654 Hyperthyroidism [ICD-11: 5A02] Approved REF00003497 DG00977 Sjogren syndrome [ICD-11: 4A43] Approved REF00003496 DG01451 Mycobacterium infection [ICD-11: 1B10-1B21] Approved REF00003493 DG01436 Blastic plasmacytoid dendritic cell neoplasm [ICD-11: 2A60] Approved REF00003491 DG01436 Acute myeloid leukaemia [ICD-11: 2A60] Approved REF00003491 DG00656 Idiopathic pulmonary fibrosis [ICD-11: CB03] Approved REF00003490 DG01245 Diabetic nephropathy [ICD-11: GB61] Approved REF00003486 DG01245 Type-1 diabetes [ICD-11: 5A10] Approved REF00003486 DG01245 Type-2 diabetes [ICD-11: 5A11] Approved REF00003486 DG01245 Type-2 diabetes [ICD-11: 5A11] Approved REF00003486 DG01158 Hypertension [ICD-11: BA00] Approved REF00003482 DG00920 Cardiovascular disease [ICD-11: BA00-BE2Z] Approved REF00003477 DG00920 Hypercholesterolaemia [ICD-11: 5C80] Approved REF00003477 DG01165 Osteoarthritis [ICD-11: FA00-FA05] Approved REF00003476 DG00961 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003475 DG00908 Acute lymphoblastic leukaemia [ICD-11: 2A70] Approved REF00003474 DG00892 Hypertension [ICD-11: BA00] Approved REF00003473 DG01363 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003472 DG01363 Pancreatic ductal carcinoma [ICD-11: 2C10] Approved REF00003472 DG01363 Melanoma [ICD-11: 2C30] Approved REF00003472 DG01363 Hepatocellular carcinoma [ICD-11: 2C12] Approved REF00003472 DG01363 Diffuse large B-cell lymphoma [ICD-11: 2A81] Approved REF00003472 DG01363 Biliary tract cancer [ICD-11: 2C15] Approved REF00003472 DG01363 Ureteral cancer [ICD-11: 2C92] Approved REF00003472 DG01304 Cholangiocarcinoma [ICD-11: 2C12] Approved REF00003471 DG01304 Myeloproliferative syndrome [ICD-11: 2A20] Approved REF00003471 DG01304 Bladder cancer [ICD-11: 2C94] Approved REF00003471 DG01306 Gastrointestinal stromal tumour [ICD-11: 2B5B] Approved REF00003470 DG01306 Systemic mastocytosis [ICD-11: 2A21] Approved REF00003470 DG01306 Mast cell leukaemia [ICD-11: 2A21] Approved REF00003470 DG00581 Cholangiocarcinoma [ICD-11: 2C12] Investigative REF00003469 DG00581 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative REF00003469 DG00581 Multiple myeloma [ICD-11: 2A83] Investigative REF00003469 DG01182 Multiple myeloma [ICD-11: 2A83] Approved REF00003466 DG01182 Primary myelofibrosis [ICD-11: 2A20] Approved REF00003466 DG01182 Type-2 diabetes [ICD-11: 5A11] Approved REF00003466 DG00630 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00003465 DG00632 Diffuse large B-cell lymphoma [ICD-11: 2A81] Investigative REF00003465 DG00677 Melanoma [ICD-11: 2C30] Approved REF00003464 DG00642 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative REF00003462 DG00642 Melanoma [ICD-11: 2C30] Investigative REF00003462 DG01315 Irritable bowel syndrome [ICD-11: DD91] Approved REF00003459 DG01315 Irritable bowel syndrome [ICD-11: DD91] Approved REF00003459 DG01315 Gastro-oesophageal reflux [ICD-11: DA22] Approved REF00003459 DG01315 Dyspepsia [ICD-11: MD92] Approved REF00003459 DG00791 Spasm [ICD-11: MB47] Approved REF00003458 DG00754 X-rays imaging [ICD-11: N.A.] Approved REF00003457 DG01148 Skin burns [ICD-11: ME65] Approved REF00003449 DG01148 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003449 DG00897 Hyperthyroidism [ICD-11: 5A02] Approved REF00003447 DG01193 Melanoma [ICD-11: 2C30] Approved REF00003446 DG01305 Crohn disease [ICD-11: DD70] Approved REF00003445 DG00915 Angina pectoris [ICD-11: BA40] Approved REF00003444 DG01216 Urinary tract infection [ICD-11: GC08] Approved REF00003442 DG00998 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003441 DG00839 Glioma [ICD-11: 2A00] Approved REF00003440 DG00839 Dietary shortage [ICD-11: 5B5K] Approved REF00003440 DG00856 Sepsis [ICD-11: 1G40] Approved REF00003439 DG01176 Obstructive airway disease [ICD-11: CB40-CB7Z] Approved REF00003438 DG01176 Asthma [ICD-11: CA23] Approved REF00003438 DG00644 Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative REF00003436 DG00644 Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative REF00003436 DG00644 Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative REF00003436 DG00608 Influenza virus infection [ICD-11: 1E30-1E32] Approved REF00003434 DG01140 Narcotic depression [ICD-11: 6A70-6A7Z] Approved REF00003433 DG01419 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003432 DG00989 Primary progressive multiple sclerosis [ICD-11: 8A40] Approved REF00003431 DG00983 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003430 DG00882 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003429 DG00914 Candidiasis [ICD-11: 1F23] Approved REF00003426 DG00941 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003425 DG00975 Chronic bronchitis [ICD-11: CA20] Approved REF00003424 DG00975 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003424 DG00919 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003422; REF00003531 DG01168 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003421 DG00945 Urinary tract infection [ICD-11: GC08] Approved REF00003420 DG01025 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003419 DG01171 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003418 DG01051 Microorganisms infection [ICD-11: 1A00-1A09] Approved REF00003417 DG01162 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003416 DG00904 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003415 DG01008 Influenza virus infection [ICD-11: 1E30-1E32] Approved REF00003414 DG01286 Human immunodeficiency virus infection [ICD-11: 1C60-1C62] Approved REF00003413 DG01286 Human immunodeficiency virus infection [ICD-11: 1C60-1C62] Approved REF00003413 DG00939 Hepatitis B virus infection [ICD-11: 1E50-1E51] Approved REF00003412 DG00939 Human immunodeficiency virus infection [ICD-11: 1C60-1C62] Approved REF00003412 DG00939 Hepatitis virus infection [ICD-11: 1E50-1E51] Approved REF00003412 DG01184 Mycobacterium infection [ICD-11: 1B10-1B21] Approved REF00003411 DG01212 Onychomycosis [ICD-11: EE12] Approved REF00003410 DG00666 Discovery agent [ICD-11: N.A.] Approved REF00003409 DG00916 Dermatomycosis [ICD-11: EA60] Approved REF00003407 DG01170 Multi-drug resistant tuberculosis [ICD-11: MG50-MG52] Approved REF00003405 DG01170 Mycobacterium infection [ICD-11: 1B10-1B21] Approved REF00003405 DG01156 Diarrhea [ICD-11: DA90] Approved REF00003404 DG01156 Infectious disease [ICD-11: 1A00-CA43] Approved REF00003404 DG01074 Pain [ICD-11: MG30] Approved REF00003401 DG01074 Diabetic neuropathy [ICD-11: 8C0Z] Approved REF00003401 DG00596 Epilepsy [ICD-11: 8A60] Approved REF00003399 DG00623 Epilepsy [ICD-11: 8A60] Approved REF00003399 DG01114 Pain [ICD-11: MG30] Approved REF00003396 DG01114 Cough [ICD-11: MD12] Approved REF00003396 DG01081 Dry eye disease [ICD-11: 9E1Z] Approved REF00003395 DG01081 Tinea pedis [ICD-11: 1F28] Approved REF00003395 DG01081 Tinea pedis [ICD-11: 1F28] Approved REF00003395 DG00660 Medulloblastoma [ICD-11: 2A00] Approved REF00003390 DG00660 Skin cancer [ICD-11: 2C30-2C37] Approved REF00003390 DG00707 Glaucoma/ocular hypertension [ICD-11: 9C61] Approved REF00003389 DG00707 Ocular hypertension [ICD-11: 9C61] Approved REF00003389 DG00823 Nausea [ICD-11: MD90] Approved REF00003388 DG01385 Reversal of the anticoagulant effects of dabigatran [ICD-11:N.A.] Approved REF00003383 DG01214 Non-small-cell lung cancer [ICD-11: 2C25] Approved REF00003379 DG01214 Non-small-cell lung cancer [ICD-11: 2C25] Approved REF00003379 DG01214 Non-small-cell lung cancer [ICD-11: 2C25] Approved REF00003379 DG00545 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative REF00003377 DG00617 Thyroid cancer [ICD-11: 2D10] Approved REF00003376 DG00617 Thyroid cancer [ICD-11: 2D10] Approved REF00003376 DG00617 Ovarian cancer [ICD-11: 2C73] Approved REF00003376 DG00619 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003376 DG01443 Plaque psoriasis [ICD-11: EA90] Approved REF00003369 DG01044 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003366 DG01082 Pain [ICD-11: MG30] Approved REF00003362 DG01262 Type-2 diabetes [ICD-11: 5A11] Approved REF00003361 DG01262 Type-2 diabetes [ICD-11: 5A11] Approved REF00003361 DG01262 Type-2 diabetes [ICD-11: 5A11] Approved REF00003361 DG01262 Type-2 diabetes [ICD-11: 5A11] Approved REF00003361 DG01262 Cardiovascular disease [ICD-11: BA00-BE2Z] Approved REF00003361 DG00937 Cardiovascular disease [ICD-11: BA00-BE2Z] Approved REF00003360 DG00662 Herpes simplex virus infection [ICD-11: 1F00] Approved REF00003354 DG00662 Virus infection [ICD-11: 1A24-1D9Z] Approved REF00003354 DG01038 Ischemic stroke [ICD-11: 8B11] Approved REF00003350 DG00933 Spasm [ICD-11: MB47] Approved REF00003348 DG01423 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003342 DG01027 Osteoarthritis [ICD-11: FA00-FA05] Approved REF00003340 DG00569 Gram-positive bacterial infection [ICD-11: 1B74-1F40] Approved REF00003337 DG00847 Obsessive compulsive disorder [ICD-11: 6B20] Approved REF00003336 DG00847 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003336 DG00847 Tuberculosis [ICD-11: 1B10] Approved REF00003336 DG01417 Bleeding disorder [ICD-11: GA20-GA21] Approved REF00003335 DG01206 Skin infection [ICD-11: 1F28-1G0Z] Approved REF00003334 DG01308 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003332 DG01050 Tuberculosis [ICD-11: 1B10] Approved REF00003331 DG01050 Mycobacterium infection [ICD-11: 1B10-1B21] Approved REF00003331 DG00681 Mycobacterium infection [ICD-11: 1B10-1B21] Approved REF00003326 DG00938 Hypertension [ICD-11: BA00] Approved REF00003325 DG01295 Heart failure [ICD-11: BD10] Approved REF00003325 DG00645 Malaria [ICD-11: 1F45] Approved REF00003321 DG00645 Malaria [ICD-11: 1F45] Approved REF00003321 DG00809 Spasm [ICD-11: MB47] Approved REF00003320 DG00966 Bacterial vaginosis [ICD-11: MF3A] Approved REF00003315 DG00966 Amoebiasis [ICD-11: 1A36] Approved REF00003315 DG00583 Glaucoma/ocular hypertension [ICD-11: 9C61] Approved REF00003314 DG00583 Glaucoma/ocular hypertension [ICD-11: 9C61] Approved REF00003314 DG00583 Ocular disease [ICD-11: 1F00] Approved REF00003314 DG00583 Open-angle glaucoma [ICD-11: 9C61] Approved REF00003314 DG00582 Alopecia [ICD-11: ED70] Approved REF00003314 DG00582 Glaucoma/ocular hypertension [ICD-11: 9C61] Approved REF00003314 DG00552 Rheumatoid arthritis [ICD-11: FA20] Approved REF00003313 DG00588 Cytomegalovirus retinitis [ICD-11: 9B72] Approved REF00003310 DG00589 Cytomegalovirus infection [ICD-11: 1D82] Approved REF00003310 DG01201 Parkinson disease [ICD-11: 8A00] Approved REF00003307 DG01201 Parkinson disease [ICD-11: 8A00] Approved REF00003307 DG00860 Myelodysplastic syndrome [ICD-11: 2A37] Approved REF00003303 DG00860 Myelodysplastic syndrome [ICD-11: 2A37] Approved REF00003303 DG01350 Plaque psoriasis [ICD-11: EA90] Approved REF00003300 DG01350 Plaque psoriasis [ICD-11: EA90] Approved REF00003300 DG01350 Asthma [ICD-11: CA23] Approved REF00003300 DG01322 Rheumatoid arthritis [ICD-11: FA20] Approved REF00003300 DG00678 Pulmonary tuberculosis [ICD-11: 1B10-1B12] Approved REF00003293 DG00883 Multiple sclerosis [ICD-11: 8A40] Approved REF00003290 DG00883 Relapsing-remitting multiple sclerosis [ICD-11: 8A40] Approved REF00003290 DG00883 Hairy cell leukaemia [ICD-11: 2A82] Approved REF00003290 DG01054 Fungal infection [ICD-11: 1F29-1F2F] Approved REF00003288 DG01460 Multiple myeloma [ICD-11: 2A83] Approved REF00003282 DG01172 Chagas disease [ICD-11: 1F53] Approved REF00003281 DG01172 Trypanosomiasis [ICD-11: 1D51-1F53] Approved REF00003281 DG01366 Ureteral cancer [ICD-11: 2C92] Approved REF00003279 DG01366 Ureteral cancer [ICD-11: 2C92] Approved REF00003279 DG00829 Hypertension [ICD-11: BA00] Approved REF00003271 DG00829 Edema [ICD-11: MG29] Approved REF00003271 DG00829 Congestive heart failure [ICD-11: BD10-BD1Z] Approved REF00003271 DG00731 Nausea [ICD-11: MD90] Approved REF00003269 DG00576 Human immunodeficiency virus infection [ICD-11: 1C60-1C62] Approved REF00003268 DG00577 Human immunodeficiency virus infection [ICD-11: 1C60-1C62] Approved REF00003268 DG00902 Schizophrenia [ICD-11: 6A20] Approved REF00003267 DG00833 Hypertension [ICD-11: BA00] Approved REF00003263 DG01190 Systemic mastocytosis [ICD-11: 2A21] Approved REF00003262 DG01190 Acute myeloid leukaemia [ICD-11: 2A60] Approved REF00003262 DG01190 Acute myeloid leukaemia [ICD-11: 2A60] Approved REF00003262 DG01190 Colorectal cancer [ICD-11: 2B91] Approved REF00003262 DG01190 Chronic myelomonocytic leukaemia [ICD-11: 2A40] Approved REF00003262 DG00718 Cough [ICD-11: MD12] Approved REF00003259 DG00953 Major depressive disorder [ICD-11: 6A70-6A7Z] Approved REF00003258 DG01238 Cystic fibrosis [ICD-11: CA25] Approved REF00003254 DG00909 Diabetic complication [ICD-11: 5A2Y] Approved REF00003252 DG00909 Cardiovascular disease [ICD-11: BA00-BE2Z] Approved REF00003252 DG01059 Polyuria [ICD-11: MF55] Approved REF00003250 DG01059 Enuresis [ICD-11: 6C00] Approved REF00003250 DG01059 Diabetes insipidus [ICD-11: 5A60-5A61] Approved REF00003250 DG00959 Hypertension [ICD-11: BA00] Approved REF00003247 DG01110 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003246 DG01198 Ovarian cancer [ICD-11: 2C73] Approved REF00003245 DG01198 Ovarian cancer [ICD-11: 2C73] Approved REF00003245 DG01439 Mantle cell lymphoma [ICD-11: 2A85] Approved REF00003239 DG01080 Chronic obstructive pulmonary disease [ICD-11: CA22] Approved REF00003238 DG01080 Human immunodeficiency virus infection [ICD-11: 1C60-1C62] Approved REF00003238 DG01013 Ovarian cancer [ICD-11: 2C73] Approved REF00003236 DG01013 Lung cancer [ICD-11: 2C25] Approved REF00003236 DG01013 Testicular cancer [ICD-11: 2C80] Approved REF00003236 DG01013 Hypercalcaemia [ICD-11: 5B91] Approved REF00003236 DG01013 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003236 DG01209 Breast cancer [ICD-11: 2C60] Approved REF00003233 DG00550 Cholangiocarcinoma [ICD-11: 2C12] Approved REF00003232 DG00547 Triple negative breast cancer [ICD-11: 2C60-2C6Y] Investigative REF00003232 DG00547 Renal cell carcinoma [ICD-11: 2C90] Investigative REF00003232 DG00554 Bladder cancer [ICD-11: 2C94] Approved REF00003232 DG00547 Endometrial cancer [ICD-11: 2C76] Investigative REF00003232 DG00554 Ureteral cancer [ICD-11: 2C92] " Phase 2" REF00003232 DG00550 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003232 DG00554 Solid tumour/cancer [ICD-11: 2A00-2F9Z] " Phase 2" REF00003232 DG00554 Lymphoma [ICD-11: 2A90- 2A85] Phase 1/2 REF00003232 DG01260 Breast cancer [ICD-11: 2C60] Approved REF00003230 DG00918 Asthma [ICD-11: CA23] Approved REF00003224 DG00799 Ventricular arrhythmias [ICD-11: BC71] Approved REF00003219 DG00572 Mycoses [ICD-11: MB47] Approved REF00003217 DG00572 Fungal infection [ICD-11: 1F29-1F2F] Approved REF00003217 DG00572 Fungal infection [ICD-11: 1F29-1F2F] Approved REF00003217 DG01091 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003196 DG01042 Hyperlipidaemia [ICD-11: 5C80] Approved REF00003195 DG01042 Multiple myeloma [ICD-11: 2A83] Approved REF00003195 DG00917 Helminth infection [ICD-11: 1F90] Approved REF00003194 DG00750 Anaesthesia [ICD-11: 8E22] Approved REF00003192 DG00750 Dysmenorrhea [ICD-11: GA34] Approved REF00003192 DG00861 Osteoporosis [ICD-11: FB83] Approved REF00003187 DG01146 Pain [ICD-11: MG30] Approved REF00003185 DG00647 Urinary tract infection [ICD-11: GC08] Approved REF00003182 DG00865 Trypanosomiasis [ICD-11: 1D51-1F53] Approved REF00003181 DG00768 Essential hypertension [ICD-11: BA00] Approved REF00003179 DG00816 Urinary tract infection [ICD-11: GC08] Approved REF00003178 DG00784 Cerebral vasospasm [ICD-11: BA85] Approved REF00003170 DG00831 Mydriasis [ICD-11: LA11] Approved REF00003169 DG00859 Musculoskeletal disorder [ICD-11: FA00-FC0Z] Approved REF00003168 DG00851 Depression [ICD-11: 6A70] Approved REF00003167 DG00621 Influenza A virus infection [ICD-11: 1E30-1E32] Approved REF00003166 DG00622 Influenza A virus infection [ICD-11: 1E30-1E32] Approved REF00003166 DG00737 High cholesterol level [ICD-11: 5C80] Approved REF00003165 DG00912 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003164 DG00812 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003161 DG00759 Heart block [ICD-11: BC63] Approved REF00003160 DG00759 Melanoma [ICD-11: 2C30] Approved REF00003160 DG01031 Ringworm infection [ICD-11: 1F28] Approved REF00003159 DG01249 Non-small-cell lung cancer [ICD-11: 2C25] Approved REF00003157 DG01249 Recurrent glioblastoma [ICD-11: 2A00] Approved REF00003157 DG01249 Hepatocellular carcinoma [ICD-11: 2C12] Approved REF00003157 DG01197 Hyperlipidaemia [ICD-11: 5C80] Approved REF00003154 DG01035 Overactive bladder [ICD-11: GC50] Approved REF00003153 DG00948 Gram-positive bacterial infection [ICD-11: 1B74-1F40] Approved REF00003152 DG00635 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative REF00003149 DG00668 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003142 DG01224 Dry eye disease [ICD-11: 9E1Z] Approved REF00003139 DG01224 Allergic conjunctivitis [ICD-11: 9A60] Approved REF00003139 DG01183 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003137 DG01203 Ocular inflammation [ICD-11: 9C61] Approved REF00003136 DG00775 Orthostatic hypotension [ICD-11: BA21] Approved REF00003134 DG01320 Rheumatoid arthritis [ICD-11: FA20] Approved REF00003131 DG01312 Hyperuricaemia [ICD-11: 5C55] Approved REF00003127 DG00818 Respiratory tract infection [ICD-11: CA07-CA4Z] Approved REF00003126 DG00573 Intestinal strongyloidiasis due to nematode parasite [ICD-11: 1F6B] Approved REF00003122 DG00687 Malaria [ICD-11: 1F45] Approved REF00003121 DG00591 Virus infection [ICD-11: 1A24-1D9Z] Approved REF00003117 DG00590 Virus infection [ICD-11: 1A24-1D9Z] Approved REF00003117 DG01039 Anabolic metabolism [ICD-11: 5C50-5C8Z] Approved REF00003111 DG00592 Amyotrophic lateral sclerosis [ICD-11: 8B60] Approved REF00003106 DG00980 Diabetic complication [ICD-11: 5A2Y] Approved REF00003105 DG00777 Skin imperfections [ICD-11: EK71] Approved REF00003096 DG00777 Depression [ICD-11: 6A70] Approved REF00003096 DG00578 Discovery agent [ICD-11: N.A.] Approved REF00003095 DG00612 Congenital adrenal hyperplasia [ICD-11: 5A71] Approved REF00003094 DG00609 Immune System disease [ICD-11: 4A01-4B41] Investigative REF00003094 DG00610 Inflammation [ICD-11: 1A00-CA43] Approved REF00003094 DG00611 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003094 DG00613 Rheumatoid arthritis [ICD-11: FA20] Approved REF00003094 DG00614 Organ transplant rejection [ICD-11: NE84] Approved REF00003094 DG00611 Spinal cord injury [ICD-11: 8C21] Approved REF00003094 DG00610 Inflammation [ICD-11: 1A00-CA43] Approved REF00003094 DG00551 Multiple sclerosis [ICD-11: 8A40] Approved REF00003094 DG00551 Arthritis [ICD-11: FA20] Approved REF00003094 DG00615 Rheumatoid arthritis [ICD-11: FA20] Approved REF00003094 DG00615 Pain [ICD-11: MG30] Approved REF00003094 DG00612 Inflammation [ICD-11: 1A00-CA43] Approved REF00003094 DG00974 Contraception [ICD-11: QA21] Approved REF00003091 DG01064 Tuberculosis [ICD-11: 1B10] Approved REF00003085 DG00679 Chemotherapy-induced nausea [ICD-11: MD90] Approved REF00003082 DG00679 Alcohol dependence [ICD-11: 6C40] Approved REF00003082 DG01267 Acute myeloid leukaemia [ICD-11: 2A60] Approved REF00003076 DG01267 Acute myeloid leukaemia [ICD-11: 2A60] Approved REF00003076 DG00580 Parkinson disease [ICD-11: 8A00] Approved REF00003071 DG00813 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003069 DG01311 Schizophrenia [ICD-11: 6A20] Approved REF00003067 DG01442 Hypothyroidism [ICD-11: 5A00] Investigative REF00003060 DG00995 Osteoarthritis [ICD-11: FA00-FA05] Approved REF00003059 DG00838 Molluscum contagiosum infection [ICD-11: 1E76] Approved REF00003058 DG01309 Colon cancer [ICD-11: 2B90] Approved REF00003052 DG01307 Non-small-cell lung cancer [ICD-11: 2C25] Approved REF00003052 DG01309 Thyroid cancer [ICD-11: 2D10] Approved REF00003052 DG01309 Non-small-cell lung cancer [ICD-11: 2C25] Approved REF00003052 DG01307 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00003052 DG00633 Osteoarthritis [ICD-11: FA00-FA05] Approved REF00003049 DG00782 High blood pressure [ICD-11: BA00] Approved REF00003047 DG00699 Epilepsy [ICD-11: 8A60] Approved REF00003043 DG00699 Anxiety disorder [ICD-11: 6B00-6B0Z] Approved REF00003043 DG01137 Tinea pedis [ICD-11: 1F28] Approved REF00003041 DG01253 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003040 DG01088 Heart arrhythmia [ICD-11: BC65] Approved REF00003039 DG00884 Asthma [ICD-11: CA23] Approved REF00003037 DG00884 Allergic rhinitis [ICD-11: CA08] Approved REF00003037 DG00819 Psoriasis vulgaris [ICD-11: EA90] Approved REF00003031 DG00804 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00003030 DG00806 Rheumatoid arthritis [ICD-11: FA20] Approved REF00003029 DG00649 Insomnia [ICD-11: 7A00] Approved REF00003027 DG00649 Epilepsy [ICD-11: 8A60] Approved REF00003027 DG00943 Cardiovascular disease [ICD-11: BA00-BE2Z] Approved REF00003017 DG00717 Intermittent claudication [ICD-11: BD40] Approved REF00003012 DG01006 Osteoarthritis [ICD-11: FA00-FA05] Approved REF00003011 DG00824 Alcohol dependence [ICD-11: 6C40] Approved REF00003008 DG00824 Neuropathic pain [ICD-11: 8E43] Approved REF00003008 DG00657 Flatworm infection [ICD-11: 1F70-1F86] Approved REF00003006 DG00702 Acute lymphoblastic leukaemia [ICD-11: 2A70] Approved REF00003001 DG00746 Chronic myelogenous leukaemia [ICD-11: 2A20] Approved REF00003000 DG00767 Major depressive disorder [ICD-11: 6A70-6A7Z] Approved REF00002997 DG01055 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00002992 DG00566 Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Approved REF00002990 DG00568 Hepatitis C virus infection [ICD-11: 1E50-1E51] Approved REF00002990 DG00585 HCV 1-6 infection [ICD-11: 1E50-1E51] Approved REF00002990 DG00564 Hepatitis C virus infection [ICD-11: 1E50-1E51] Approved REF00002990 DG00564 Hepatitis C virus infection [ICD-11: 1E50-1E51] Approved REF00002990 DG00585 Hepatitis C virus infection [ICD-11: 1E50-1E51] Approved REF00002990 DG00600 Hepatitis C virus infection [ICD-11: 1E50-1E51] Investigative REF00002990 DG00606 Hepatitis C virus infection [ICD-11: 1E50-1E51] Investigative REF00002990 DG00602 Hepatitis C virus infection [ICD-11: 1E50-1E51] Approved REF00002990 DG00584 Hepatitis C virus infection [ICD-11: 1E50-1E51] Approved REF00002990 DG00604 Hepatitis C virus infection [ICD-11: 1E50-1E51] Approved REF00002990 DG00603 Hepatitis C virus infection [ICD-11: 1E50-1E51] Approved REF00002990 DG00607 Chronic HCV-1 infection [ICD-11: 1E50-1E51] Approved REF00002990 DG00567 Chronic HCV-1 infection [ICD-11: 1E50-1E51] Approved REF00002990 DG00605 Hepatitis C virus infection [ICD-11: 1E50-1E51] Approved REF00002990 DG00563 Hepatitis C virus infection [ICD-11: 1E50-1E51] Approved REF00002990 DG00565 Hepatitis C virus infection [ICD-11: 1E50-1E51] Approved REF00002990 DG00599 Hepatitis virus infection [ICD-11: 1E50-1E51] Approved REF00002990 DG00601 Hepatitis virus infection [ICD-11: 1E50-1E51] Approved REF00002990 DG00705 Prostate cancer [ICD-11: 2C82] Approved REF00002983 DG00574 Parkinson disease [ICD-11: 8A00] Approved REF00002976 DG00751 Friedreich's ataxia [ICD-11: 8A03] Approved REF00002974 DG00751 Cognitive impairment [ICD-11: 6D71] Approved REF00002974 DG01047 Acromegaly [ICD-11: 5A60-5A61] Approved REF00002972 DG01265 Breast cancer [ICD-11: 2C60] Approved REF00002971 DG01266 Breast cancer [ICD-11: 2C60] Approved REF00002971 DG01264 Breast cancer [ICD-11: 2C60] Approved REF00002971 DG01266 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00002971 DG01264 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00002971 DG01265 Schizophrenia [ICD-11: 6A20] Approved REF00002971 DG01265 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00002971 DG01368 Migraine [ICD-11: 8A80] Approved REF00002965 DG01185 Peptic ulcer [ICD-11: DA61] Approved REF00002959 DG00849 Virus infection [ICD-11: 1A24-1D9Z] Approved REF00002957 DG01239 Myelofibrosis [ICD-11: 2A20] Approved REF00002953 DG00895 Breast cancer [ICD-11: 2C60] Approved REF00002953 DG00895 Menorrhagia [ICD-11: GA20] Approved REF00002953 DG00830 Schizophrenia [ICD-11: 6A20] Approved REF00002948 DG00872 Cerebrovascular ischaemia [ICD-11: 8B1Z] Approved REF00002946 DG00979 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00002938 DG00543 Diffuse large B-cell lymphoma [ICD-11: 2A81] Approved REF00002934 DG00542 Acute lymphoblastic leukaemia [ICD-11: 2A70] Approved REF00002933 DG00541 Hodgkin lymphoma [ICD-11: 2B30] Approved REF00002932 DG00540 Acute myeloid leukaemia [ICD-11: 2A60] Approved REF00002930 DG00291 Discovery agent [ICD-11: N.A.] Investigative REF00002900 DG00450 Gonococcal infection [ICD-11: 1A72] Approved REF00002898 DG00290 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00002898 DG00231 Bacterial infection [ICD-11: 1A00-1C4Z] Clinical trial REF00002883 DG00059 Gonococcal infection [ICD-11: 1A72] Approved REF00002876 DG00432 Discovery agent [ICD-11: N.A.] Investigative REF00002873 DG00013 Nail/perionychium infection [ICD-11: EE12] Phase 2 REF00002872 DG00245 Nail/perionychium infection [ICD-11: EE12] Approved REF00002872 DG00083 Discovery agent [ICD-11: N.A.] Investigative REF00002872 DG00234 Psychotic disorder [ICD-11: 6A20-6A25] Approved REF00002872 DG00013 Fungal infection [ICD-11: 1F29-1F2F] Approved REF00002872 DG00051 concerning food/fluid intake symptom [ICD-11: MG43] Approved REF00002872 DG00249 Hypertension [ICD-11: BA00] Approved REF00002865 DG00484 Infectious gastroenteritis/colitis [ICD-11: 1A40] Investigative REF00002844 DG00009 Bacterial infection [ICD-11: 1A00-1C4Z] Investigative REF00002841 DG00265 Discovery agent [ICD-11: N.A.] Investigative REF00002824 DG00104 Discovery agent [ICD-11: N.A.] Investigative REF00002823 DG00211 Malaria [ICD-11: 1F45] Phase 2 REF00002815 DG00077 Malaria [ICD-11: 1F45] Approved REF00002814 DG00058 Malaria [ICD-11: 1F45] Approved REF00002814 DG00404 Inborn purine/pyrimidine/nucleotide metabolism error [ICD-11: 5C55] Approved REF00002808 DG00404 Gout [ICD-11: FA25] Approved REF00002808 DG00067 Bronchitis [ICD-11: CA20] Approved REF00002804; REF00002867 DG00143 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00002804; REF00002867 DG00203 Hyperlipoproteinaemia [ICD-11: 5C80] Approved REF00002801; REF00002816 DG00203 Blood/blood-forming organ sympton [ICD-11: MA14] Phase 3 REF00002801; REF00002816 DG00039 Irritable bowel syndrome [ICD-11: DD91] Approved REF00002801 DG00039 Rheumatoid arthritis [ICD-11: FA20] Approved REF00002801 DG00296 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00002801 DG00019 Vasomotor/allergic rhinitis [ICD-11: CA08] Approved REF00002801 DG00223 Malaria [ICD-11: 1F45] Approved REF00002794 DG00461 Acute diabete complication [ICD-11: 5A2Y] Approved REF00002788 DG00102 Rheumatoid arthritis [ICD-11: FA20] Phase 3 REF00002786 DG00102 Multiple sclerosis [ICD-11: 8A40] Approved REF00002786 DG00102 Hyperlipoproteinaemia [ICD-11: 5C80] Approved REF00002786 DG00102 Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 1 REF00002786 DG00116 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Phase 3 REF00002782 DG00109 Liver cancer [ICD-11: 2C12] Phase 3 REF00002781 DG00109 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00002781 DG00109 Breast cancer [ICD-11: 2C60] Phase 2 REF00002781 DG00154 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00002780 DG00346 Stomach cancer [ICD-11: 2B72] Application submitted REF00002779 DG00346 Breast cancer [ICD-11: 2C60] Approved REF00002779 DG00325 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Approved REF00002775 DG00011 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Approved REF00002775 DG00246 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Approved REF00002775 DG00197 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Approved REF00002775 DG00300 Colorectal cancer [ICD-11: 2B91] Approved REF00002773 DG00074 Lung cancer [ICD-11: 2C25] Approved REF00002772 DG00151 Stomach cancer [ICD-11: 2B72] Phase 2 REF00002764 DG00151 Ovarian cancer [ICD-11: 2C73] Phase 2 REF00002764 DG00151 Pancreatic cancer [ICD-11: 2C10] Phase 3 REF00002764 DG00151 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00002764 DG00151 Breast cancer [ICD-11: 2C60] Approved REF00002764 DG00130 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00002763 DG00130 Pancreatic cancer [ICD-11: 2C10] Phase 3 REF00002763 DG00130 Malignant haematopoietic neoplasm [ICD-11: 2B33] Phase 3 REF00002763 DG00130 Follicular lymphoma [ICD-11: 2A80] Phase 3 REF00002763 DG00130 Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3 REF00002763 DG00130 Mature B-cell lymphoma [ICD-11: 2A85] Approved REF00002763 DG00133 Mature B-cell lymphoma [ICD-11: 2A85] Approved REF00002761 DG00049 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00002759 DG00072 Melanoma [ICD-11: 2C30] Approved REF00002757 DG00023 Kaposi sarcoma [ICD-11: 2B57] Approved REF00002756 DG00023 Acute myeloid leukaemia [ICD-11: 2A60] Approved REF00002756 DG00023 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00002756 DG00250 Gastrointestinal stromal tumour [ICD-11: 2B5B] Approved REF00002753 DG00250 Malignant digestive organ neoplasm [ICD-11: 2C11] Approved REF00002753 DG00323 Leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 1 REF00002751 DG00294 Ovarian cancer [ICD-11: 2C73] Approved REF00002751 DG00144 Mature B-cell lymphoma [ICD-11: 2A85] Approved REF00002747 DG00144 Mastocytosis [ICD-11: 2A21] Investigative REF00002747 DG00144 Myeloproliferative neoplasm [ICD-11: 2A22] Approved REF00002747 DG00144 Malignant intestine neoplasm [ICD-11: 2C0Z] Phase 3 REF00002747 DG00144 Lung cancer [ICD-11: 2C25] Phase 2 REF00002747 DG00095 Breast cancer [ICD-11: 2C60] Approved REF00002745 DG00187 Skin and skin-structure infection [ICD-11: 1F28-1G0Z] Approved REF00002744 DG00137 Urethral cancer [ICD-11: 2C93] Phase 2 REF00002743 DG00137 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00002743 DG00137 Head and neck cancer [ICD-11: 2D42] Phase 3 REF00002743 DG00282 Renal cell carcinoma [ICD-11: 2C90] Approved REF00002738 DG00282 Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 REF00002738 DG00282 Liver cancer [ICD-11: 2C12] Phase 3 REF00002738 DG00320 Inborn energy metabolism error [ICD-11: 5C53] Phase 3 REF00002734 DG00320 Insulin-resistance syndrome [ICD-11: 5A44] Phase 4 REF00002734 DG00320 Idiopathic interstitial pneumonitis [ICD-11: CB03] Phase 1 REF00002734 DG00444 Glanders [ICD-11: 1B92] Approved REF00002729 DG00153 Brain cancer [ICD-11: 2A00] Approved REF00002727 DG00228 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00002724 DG00340 Colorectal cancer [ICD-11: 2B91] Approved REF00002723 DG00108 Mature B-cell lymphoma [ICD-11: 2A85] Approved REF00002717 DG00314 Adrenal cancer [ICD-11: 2D11] Approved REF00002709 DG00329 Hypo-thyroidism [ICD-11: 5A00] Approved REF00002705 DG00099 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00002700 DG00053 Lung cancer [ICD-11: 2C25] Phase 2 REF00002690 DG00053 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 REF00002690 DG00050 Lung cancer [ICD-11: 2C25] Approved REF00002690 DG00163 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00002688 DG00193 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00002688 DG00037 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00002688 DG00227 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00002688 DG00048 Gram-positive bacterial infection [ICD-11: 1B74-1F40] Phase 3 REF00002688 DG00048 Urinary tract infection [ICD-11: GC08] Approved REF00002688 DG00328 Respiratory infection [ICD-11: CA07-CA4Z] Phase 4 REF00002688 DG00299 Acute bronchitis [ICD-11: CA42] Approved REF00002687 DG00195 Renal cell carcinoma [ICD-11: 2C90] Phase 2 REF00002686 DG00337 Breast cancer [ICD-11: 2C60] Approved REF00002681 DG00266 Mature B-cell lymphoma [ICD-11: 2A85] Approved REF00002673 DG00266 Multiple myeloma [ICD-11: 2A83] Approved REF00002673 DG00266 Malignant haematopoietic neoplasm [ICD-11: 2B33] Phase 3 REF00002673 DG00014 Discovery agent [ICD-11: N.A.] Investigative REF00002651 DG00148 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00002642 DG00159 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00002638 DG00199 Eczema [ICD-11: EA80-EA89] Phase 1 REF00002633 DG00199 Atopic eczema [ICD-11: EA80] Phase 1 REF00002633 DG00199 Postoperative inflammation [ICD-11: 1A00-CA43] Approved REF00002633 DG00200 Rheumatoid arthritis [ICD-11: FA20] Approved REF00002633 DG00267 Vitreoretinopathy [ICD-11: 9B78] Phase 3 REF00002618 DG00267 Prostate cancer [ICD-11: 2C82] Investigative REF00002618 DG00267 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 REF00002618 DG00267 Leukaemia [ICD-11: 2A60-2B33] Approved REF00002618 DG00267 Rheumatoid arthritis [ICD-11: FA20] Phase 1 REF00002618 DG00330 Lung cancer [ICD-11: 2C25] Registered REF00002616 DG00101 Pancreatic cancer [ICD-11: 2C10] Phase 3 REF00002616 DG00101 Lung cancer [ICD-11: 2C25] Approved REF00002616 DG00101 Colon cancer [ICD-11: 2B90] Phase 2 REF00002616 DG00544 Pancreatic cancer [ICD-11: 2C10] Phase 3 REF00002616 DG00544 Lung cancer [ICD-11: 2C25] Approved REF00002616 DG00544 Colon cancer [ICD-11: 2B90] Phase 2 REF00002616 DG00204 Breast cancer [ICD-11: 2C60] Approved REF00002614 DG00087 Preterm labour/delivery [ICD-11: JB00] Approved REF00002604 DG00087 Contraceptive management [ICD-11: QA21] Phase 3 REF00002604 DG00007 Myeloproliferative neoplasm [ICD-11: 2A22] Approved REF00002561 DG00174 Myeloproliferative neoplasm [ICD-11: 2A22] Approved REF00002561 DG00174 Multiple myeloma [ICD-11: 2A83] Phase 2 REF00002561 DG00338 Malignant haematopoietic neoplasm [ICD-11: 2B33] Approved REF00002554 DG00338 Pemphigus [ICD-11: EB40] Phase 3 REF00002554 DG00297 Malignant digestive organ neoplasm [ICD-11: 2C11] Approved REF00002542 DG00297 Breast cancer [ICD-11: 2C60] Approved REF00002542 DG00297 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00002542 DG00274 Epilepsy/seizure [ICD-11: 8A61-8A6Z] Phase 3 REF00002541 DG00327 Cardiovascular disease [ICD-11: BA00-BE2Z] Approved REF00002541 DG00274 Mood/affect symptom [ICD-11: MB24] Approved REF00002541 DG00002 Liver cancer [ICD-11: 2C12] Phase 3 REF00002538 DG00002 Multiple myeloma [ICD-11: 2A83] Approved REF00002538 DG00125 Malaria [ICD-11: 1F45] Approved REF00002531; REF00002793; REF00002805; REF00002814 DG00232 Malaria [ICD-11: 1F45] Approved REF00002531; REF00002793; REF00002805; REF00002814 DG00119 Discovery agent [ICD-11: N.A.] Investigative REF00002517 DG00317 Discovery agent [ICD-11: N.A.] Investigative REF00002504 DG00032 Ovarian cancer [ICD-11: 2C73] Approved REF00002496 DG00032 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00002496 DG00032 Lung cancer [ICD-11: 2C25] Phase 1 REF00002496 DG00305 Melanoma [ICD-11: 2C30] Approved REF00002491 DG00335 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00002472 DG00115 Breast cancer [ICD-11: 2C60] Approved REF00002460 DG00165 Type 2 diabetes mellitus [ICD-11: 5A11] Approved REF00002447 DG00261 Periodontal disease [ICD-11: DA0C] Approved REF00002431 DG00261 Gingival/edentulous alveolar ridge disorder [ICD-11: DA0D] Approved REF00002431 DG00106 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00002431 DG00261 Diabetic foot ulcer [ICD-11: BD54] Phase 2 REF00002431 DG00090 Discovery agent [ICD-11: N.A.] Investigative REF00002428 DG00405 Dental disease [ICD-11: DA08] Approved REF00002418 DG00214 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00002406 DG00214 Osteosarcoma [ICD-11: 2B51] Phase 2 REF00002406 DG00214 Malignant haematopoietic neoplasm [ICD-11: 2B33] Phase 2 REF00002406 DG00132 Cough [ICD-11: MD12] Approved REF00002396 DG00158 Bowel habit change [ICD-11: ME05] Approved REF00002396 DG00198 Motor neuron disease [ICD-11: 8B60] Preclinical REF00002391 DG00118 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00002355 DG00107 Candidosis [ICD-11: 1F23] Phase 3 REF00002346 DG00107 Aspergillosis [ICD-11: 1F20] Phase 3 REF00002346 DG00036 Candidosis [ICD-11: 1F23] Phase 3 REF00002342 DG00079 Candidosis [ICD-11: 1F23] Approved REF00002342 DG00185 Epilepsy/seizure [ICD-11: 8A61-8A6Z] Approved REF00002342 DG00306 Melanoma [ICD-11: 2C30] Approved REF00002323 DG00020 Brain cancer [ICD-11: 2A00] Approved REF00002321 DG00020 Liver cancer [ICD-11: 2C12] Approved REF00002321 DG00332 Renal cell carcinoma [ICD-11: 2C90] Approved REF00002310 DG00010 Influenza [ICD-11: 1E30] Phase 2 REF00002302 DG00293 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00002294 DG00026 Liver disease [ICD-11: DB90-DB9Z] Phase 2/3 REF00002272 DG00052 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00002268 DG00103 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 REF00002220 DG00434 Myelodysplastic syndrome [ICD-11: 2A37] Approved REF00002212 DG00331 Breast cancer [ICD-11: 2C60] Phase 2 REF00002205 DG00331 Renal cell carcinoma [ICD-11: 2C90] Phase 3 REF00002205 DG00331 Endometrial cancer [ICD-11: 2C76] Phase 2 REF00002205 DG00429 Psoriasis [ICD-11: EA90] Phase 2/3 REF00002166 DG00429 Malignant haematopoietic neoplasm [ICD-11: 2B33] Phase 3 REF00002166 DG00429 Acute myeloid leukaemia [ICD-11: 2A60] Approved (orphan drug) REF00002166 DG00192 Mature B-cell lymphoma [ICD-11: 2A85] Approved REF00002156 DG00262 Malaria [ICD-11: 1F45] Approved REF00002143 DG00171 Diabetes mellitus [ICD-11: 5A10] Investigative REF00002121 DG00295 Fungal infection [ICD-11: 1F29-1F2F] Approved REF00002113 DG00006 Discovery agent [ICD-11: N.A.] Investigative REF00002102 DG00196 Discovery agent [ICD-11: N.A.] Investigative REF00002095 DG00080 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00002077 DG00080 Dissociative neurological symptom disorder [ICD-11: 6B60] Investigative REF00002077 DG00021 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00002069; REF00002804 DG00062 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00002069; REF00002804 DG00339 Breast cancer [ICD-11: 2C60] Phase 3 REF00002067 DG00342 Breast cancer [ICD-11: 2C60] Approved REF00002067 DG00268 Hair/hair growth developmental defect [ICD-11: LC30] Approved REF00002059 DG00322 Brain cancer [ICD-11: 2A00] Phase 2 REF00002049 DG00045 Multiple myeloma [ICD-11: 2A83] Approved REF00002046 DG00045 Transplant rejection [ICD-11: NE84] Approved REF00002046 DG00045 Hydrocephalus [ICD-11: 8D64] Phase 1/2 REF00002046 DG00292 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative REF00002044 DG00292 Skin disease [ICD-11: EA00-EM0Z] Investigative REF00002044 DG00066 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00002037 DG00255 Discovery agent [ICD-11: N.A.] Investigative REF00002022 DG00281 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00001997 DG00336 Gram-positive bacterial infection [ICD-11: 1B74-1F40] Investigative REF00001993 DG00175 Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2 REF00001993 DG00175 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00001993 DG00270 Lung cancer [ICD-11: 2C25] Approved REF00001979 DG00253 Lymphoma [ICD-11: 2A90- 2A85] Investigative REF00001979 DG00425 Discovery agent [ICD-11: N.A.] Investigative REF00001956 DG00419 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00001956 DG00421 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00001956 DG00016 Sepsis [ICD-11: 1G40] Approved REF00001956 DG00088 Colorectal cancer [ICD-11: 2B91] Approved REF00001950 DG00341 Head and neck cancer [ICD-11: 2D42] Phase 2 REF00001943 DG00341 Colorectal cancer [ICD-11: 2B91] Approved REF00001943 DG00254 Malignant haematopoietic neoplasm [ICD-11: 2B33] Phase 1/2 REF00001927 DG00254 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00001927 DG00213 Renal cell carcinoma [ICD-11: 2C90] Phase 3 REF00001925 DG00213 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00001925 DG00092 Urinary tract infection [ICD-11: GC08] Approved REF00001908 DG00240 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00001905 DG00117 Rosacea [ICD-11: ED90] Phase 2 REF00001892 DG00256 Glanders [ICD-11: 1B92] Approved REF00001892 DG00201 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00001892 DG00117 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00001892 DG00235 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00001872; REF00002826 DG00084 Aspergillosis [ICD-11: 1F20] Approved REF00001864 DG00216 Lung cancer [ICD-11: 2C25] Phase 3 REF00001844; REF00001900; REF00002211 DG00312 Schizophrenia [ICD-11: 6A20] Approved REF00001786 DG00034 Prostate cancer [ICD-11: 2C82] Approved REF00001776 DG00247 Prostate cancer [ICD-11: 2C82] Approved REF00001776 DG00167 Malaria [ICD-11: 1F45] Approved REF00001754 DG00324 Leukaemia [ICD-11: 2A60-2B33] Approved REF00001753 DG00128 Peritoneal cancer [ICD-11: 2C51] Phase 3 REF00001742 DG00128 Idiopathic interstitial pneumonitis [ICD-11: CB03] Approved REF00001742 DG00128 Ovarian cancer [ICD-11: 2C73] Phase 2 REF00001742 DG00128 Lung cancer [ICD-11: 2C25] Phase 3 REF00001742 DG00128 Colorectal cancer [ICD-11: 2B91] Approved REF00001742 DG00071 Lung cancer [ICD-11: 2C25] Approved REF00001737 DG00017 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00001733 DG00275 Multiple myeloma [ICD-11: 2A83] Approved REF00001727 DG00189 COVID-19 [ICD-11: 1D92] Phase 1 REF00001706 DG00124 Gout [ICD-11: FA25] Approved REF00001706 DG00287 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Approved REF00001700 DG00091 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Approved REF00001700 DG00272 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Approved REF00001700 DG00248 COVID-19 [ICD-11: 1D92] Investigative REF00001696 DG00344 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00001693 DG00344 Renal cell carcinoma [ICD-11: 2C90] Phase 3 REF00001693 DG00344 Prostate cancer [ICD-11: 2C82] Phase 2 REF00001693 DG00344 Ovarian cancer [ICD-11: 2C73] Phase 2 REF00001693 DG00344 Lung cancer [ICD-11: 2C25] Phase 3 REF00001693 DG00344 Liver cancer [ICD-11: 2C12] Phase 3 REF00001693 DG00344 Esophageal cancer [ICD-11: 2B70] Phase 3 REF00001693 DG00344 Diffuse large B-cell lymphoma [ICD-11: 2A81] Application submitted REF00001693 DG00344 Colorectal cancer [ICD-11: 2B91] Phase 3 REF00001693 DG00344 Breast cancer [ICD-11: 2C60] Phase 3 REF00001693 DG00344 Melanoma [ICD-11: 2C30] Approved REF00001693 DG00140 Corneal disease [ICD-11: 9A76-9A78] Approved REF00001692 DG00438 Breast cancer [ICD-11: 2C60] Approved REF00001681 DG00136 HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] Approved REF00001674 DG00168 Sensation disturbance [ICD-11: MB40] Approved REF00001663 DG00168 Pain [ICD-11: MG30] Phase 3 REF00001663 DG00168 Chronic pain [ICD-11: MG30] Phase 3 REF00001663 DG00112 Mature B-cell lymphoma [ICD-11: 2A85] Approved REF00001662 DG00222 Aspergillosis [ICD-11: 1F20] Approved REF00001657 DG00260 Melanoma [ICD-11: 2C30] Phase 1 REF00001649 DG00273 Osteosarcoma [ICD-11: 2B51] Phase 2 REF00001639; REF00002251; REF00002276 DG00273 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00001639; REF00002251; REF00002276 DG00138 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 REF00001635 DG00289 Discovery agent [ICD-11: N.A.] Investigative REF00001634 DG00022 Contraceptive management [ICD-11: QA21] Approved REF00001625 DG00086 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00001622 DG00029 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Approved REF00001620 DG00286 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00001619 DG00202 Prostate cancer [ICD-11: 2C82] Phase 3 REF00001617 DG00202 Pancreatic cancer [ICD-11: 2C10] Phase 3 REF00001617 DG00202 Ovarian cancer [ICD-11: 2C73] Approved REF00001617 DG00403 Breast cancer [ICD-11: 2C60] Approved REF00001616 DG00044 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Approved REF00001611 DG00229 Lung cancer [ICD-11: 2C25] Approved REF00001607 DG00229 Melanoma [ICD-11: 2C30] Phase 3 REF00001607 DG00042 Brain cancer [ICD-11: 2A00] Phase 2 REF00001578 DG00042 Basal cell carcinoma [ICD-11: 2C32] Approved REF00001578 DG01586 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 REF00001577 DG01586 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 REF00001577 DG01586 Chronic lymphocytic leukaemia [ICD-11: 2A82] Phase 1/2 REF00001577 DG01579 Myelofibrosis [ICD-11: 2A20] Phase 1 REF00001577 DG00280 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00001567 DG00206 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1/2 REF00001567 DG00177 Renal cell carcinoma [ICD-11: 2C90] Approved REF00001567 DG00208 Renal cell carcinoma [ICD-11: 2C90] Approved REF00001567 DG00321 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00001566; REF00002560 DG00225 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00001565; REF00001977 DG00225 Cystic fibrosis [ICD-11: CA25] Phase 2 REF00001565; REF00001977 DG00225 Gram-positive bacterial infection [ICD-11: 1B74-1F40] Approved REF00001565; REF00001977 DG00225 Digestive organ benign neoplasm [ICD-11: 2E92] Phase 1 REF00001565; REF00001977 DG00301 HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] Investigative REF00001539 DG00085 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00001539 DG00301 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00001539 DG00284 Breast cancer [ICD-11: 2C60] Approved REF00001518; REF00001844 DG00284 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00001518; REF00001844 DG00176 Mycosis fungoides [ICD-11: 2B01] Approved REF00001479 DG00304 Pleural mesothelioma [ICD-11: 2C26] Approved REF00001479 DG00015 Mature B-cell lymphoma [ICD-11: 2A85] Approved REF00001463 DG00191 Malaria [ICD-11: 1F45] Approved REF00001447; REF00002814 DG00309 Lymphoma [ICD-11: 2A90- 2A85] Phase 2 REF00001435 DG00316 Discovery agent [ICD-11: N.A.] Investigative REF00001435 DG00209 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00001425 DG00098 Malaria [ICD-11: 1F45] Approved REF00001416 DG00134 Mature B-cell lymphoma [ICD-11: 2A85] Approved REF00001406 DG00040 Acute myeloid leukaemia [ICD-11: 2A60] Approved REF00001406 DG00134 Crohn disease [ICD-11: DD70] Phase 4 REF00001406 DG00055 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00001395; REF00001801; REF00002839 DG00343 Pancreatic cancer [ICD-11: 2C10] Phase 1 REF00001382 DG00343 Mature B-cell lymphoma [ICD-11: 2A85] Phase 3 REF00001382 DG00056 Lung cancer [ICD-11: 2C25] Approved REF00001377 DG00041 Malaria [ICD-11: 1F45] Approved REF00001376; REF00002455 DG00244 Breast cancer [ICD-11: 2C60] Phase 3 REF00001374 DG00073 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00001362 DG00181 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Approved REF00001358 DG00333 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Approved REF00001358 DG00178 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Approved REF00001358 DG00333 Coronavirus infection [ICD-11: 1D92] Approved REF00001358 DG00334 Melanoma [ICD-11: 2C30] Phase 2 REF00001349 DG00334 Malignant mesenchymal neoplasm [ICD-11: 2B5D-2B5Y] Phase 3 REF00001349 DG00334 Ovarian cancer [ICD-11: 2C73] Phase 3 REF00001349 DG00334 Lung cancer [ICD-11: 2C25] Phase 3 REF00001349 DG00334 Breast cancer [ICD-11: 2C60] Phase 3 REF00001349 DG00081 Hodgkin lymphoma [ICD-11: 2B30] Approved REF00001330 DG00241 Multiple myeloma [ICD-11: 2A83] Approved REF00001318; REF00001880 DG00422 Breast cancer [ICD-11: 2C60] Approved REF00001301; REF00001681 DG00397 Breast cancer [ICD-11: 2C60] Approved REF00001301; REF00001681 DG00218 Myeloproliferative neoplasm [ICD-11: 2A22] Approved REF00001291 DG00277 Renal cell carcinoma [ICD-11: 2C90] Phase 3 REF00001287 DG00277 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00001287 DG00277 Mature T-cell lymphoma [ICD-11: 2A90] Phase 2 REF00001287 DG00277 Gynecologic cancer [ICD-11: 2F33-2F76] Phase 2 REF00001287 DG00277 Follicular lymphoma [ICD-11: 2A80] Phase 3 REF00001287 DG00277 Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 REF00001287 DG00277 Breast cancer [ICD-11: 2C60] Phase 2 REF00001287 DG00277 Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 REF00001287 DG00024 Virus infection [ICD-11: 1A24-1D9Z] Investigative REF00001267 DG00141 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Approved REF00001267 DG00226 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Approved REF00001267 DG00075 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Approved REF00001267 DG00024 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Approved REF00001267 DG00315 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Approved REF00001267 DG00269 Pain [ICD-11: MG30] Investigative REF00001267 DG00269 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Approved REF00001267 DG00236 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00001260 DG00093 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00001260 DG00212 Menopausal disorder [ICD-11: GA30] Phase 2/3 REF00001258 DG00212 Prostate cancer [ICD-11: 2C82] Phase 2 REF00001258 DG00164 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00001246 DG00164 Multiple sclerosis [ICD-11: 8A40] Phase 3 REF00001246 DG00146 Infectious meningitis [ICD-11: 1D01] Investigative REF00001245 DG00146 Anaerobic bacterial infection [ICD-11: 1A00-1A09] Approved REF00001245 DG00076 Clostridium difficile enterocolitis [ICD-11: 1A04] Approved REF00001245 DG00230 Breast cancer [ICD-11: 2C60] Approved REF00001231; REF00001598 DG00326 Discovery agent [ICD-11: N.A.] Investigative REF00001212 DG00031 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00001188; REF00002480; REF00002512 DG00120 Unspecific body region injury [ICD-11: ND56] Approved REF00001187 DG00120 Skin postprocedural disorder [ICD-11: EL8Y] Phase 2 REF00001187 DG00215 Skin and skin-structure infection [ICD-11: 1F28-1G0Z] Approved REF00001181 DG00479 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00001181 DG00166 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Approved REF00001139; REF00001651; REF00002436 DG00157 Hepatitis virus infection [ICD-11: 1E50-1E51] Approved REF00001139; REF00001651; REF00002436 DG00008 Discovery agent [ICD-11: N.A.] Investigative REF00001139; REF00001651; REF00002436 DG00210 Hepatitis virus infection [ICD-11: 1E50-1E51] Approved REF00001139; REF00001651; REF00002436 DG00224 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative REF00001135 DG00319 Escherichia coli intestinal infection [ICD-11: 1A03] Phase 2 REF00001130 DG00257 Urinary tract infection [ICD-11: GC08] Approved REF00001130 DG00003 Colorectal cancer [ICD-11: 2B91] Approved REF00001109 DG00003 Breast cancer [ICD-11: 2C60] Phase 3 REF00001109 DG00060 Pneumonia [ICD-11: CA40] Approved REF00001098 DG00082 Metastatic tumour [ICD-11: 2D50-2E2Z] Phase 2 REF00001082 DG00082 Metastatic meninges neoplasm [ICD-11: 2D51] Phase 2 REF00001082 DG00082 Brain cancer [ICD-11: 2A00] Phase 2 REF00001082 DG00082 Cystic/dysplastic kidney disease [ICD-11: GB8Y] Phase 2 REF00001082 DG00082 Lung cancer [ICD-11: 2C25] Phase 2 REF00001082 DG00122 Clostridium difficile enterocolitis [ICD-11: 1A04] Phase 2 REF00001072 DG00179 Malignant haematopoietic neoplasm [ICD-11: 2B33] Approved REF00001069 DG00096 Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 REF00001061; REF00001171 DG00096 Leukaemia [ICD-11: 2A60-2B33] Phase 3 REF00001061; REF00001171 DG00205 Breast cancer [ICD-11: 2C60] Phase 2 REF00001055 DG00063 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00001049; REF00001236 DG00303 Bacterial infection [ICD-11: 1A00-1C4Z] Withdrawn from market REF00001044 DG00030 Heart failure [ICD-11: BD10] Approved REF00001043 DG00030 Cardiac arrhythmia [ICD-11: BC9Z] Approved REF00001043 DG00121 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00001034 DG00068 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00001005 DG00068 Alcoholic liver disease [ICD-11: DB94] Approved REF00001005 DG00068 Acute/subacute hepatic failure [ICD-11: DB91] Approved REF00001005 DG00239 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000993 DG00069 Colorectal cancer [ICD-11: 2B91] Investigative REF00000984; REF00002238 DG00069 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00000984; REF00002238 DG00180 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000976 DG00100 Malaria [ICD-11: 1F45] Approved REF00000942 DG00345 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000923 DG00126 Fungal infection [ICD-11: 1F29-1F2F] Approved REF00000913 DG00142 Urinary tract infection [ICD-11: GC08] Approved REF00000904 DG00027 Acute myeloid leukaemia [ICD-11: 2A60] Approved REF00000893; REF00001636 DG00027 Acne vulgaris [ICD-11: ED80] Approved REF00000893; REF00001636 DG00078 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000882; REF00001021; REF00001203; REF00001517; REF00001588; REF00002809 DG00018 Rectum cancer [ICD-11: 2B92] Approved REF00000874 DG00001 Malaria [ICD-11: 1F45] Approved REF00000872 DG00001 Trypanosomiasis [ICD-11: 1D51-1F53] Investigative REF00000872 DG00238 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000839 DG00233 Bowel habit change [ICD-11: ME05] Approved REF00000817 DG00161 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3 REF00000814 DG00276 Discovery agent [ICD-11: N.A.] Approved REF00000811 DG00043 Syphilis [ICD-11: 1A61-1A6Z] Approved REF00000798 DG00105 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Approved REF00000790 DG00105 Hepatitis virus infection [ICD-11: 1E50-1E51] Approved REF00000790 DG00400 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000775; REF00002858 DG00094 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000775; REF00002858 DG00170 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000770 DG00288 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000770 DG00149 Vasomotor/allergic rhinitis [ICD-11: CA08] Approved REF00000756 DG00184 Gram-positive bacterial infection [ICD-11: 1B74-1F40] Withdrawn from market REF00000749; REF00001122; REF00002827 DG00129 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000749; REF00001122; REF00002827 DG00057 Amoebiasis [ICD-11: 1A36] Approved REF00000730 DG00162 Schizophrenia [ICD-11: 6A20] Approved REF00000724 DG00025 Schizophrenia [ICD-11: 6A20] Approved REF00000724 DG00033 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000713; REF00001092 DG00318 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000713; REF00001092 DG00402 Nasopharyngeal cancer [ICD-11: 2B6B] Investigative REF00000712 DG00054 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000712 DG00402 Lung cancer [ICD-11: 2C25] Phase 3 REF00000712 DG00441 Irritable bowel syndrome [ICD-11: DD91] Approved REF00000712 DG00414 Acquired methaemoglobinaemia [ICD-11: 3A93] Approved REF00000712 DG00433 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Phase 1 REF00000712 DG00396 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated REF00000708 DG00169 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000705 DG00012 Fungal infection [ICD-11: 1F29-1F2F] Approved REF00000701 DG00413 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000690 DG00415 Skin and skin-structure infection [ICD-11: 1F28-1G0Z] Approved REF00000690 DG00413 HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] Approved REF00000690 DG00089 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Approved REF00000686 DG00035 Urinary tract infection [ICD-11: GC08] Approved REF00000682; REF00002884 DG00308 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000682; REF00002884 DG00220 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000682; REF00002884 DG00183 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000682; REF00002884 DG00278 Fungal infection [ICD-11: 1F29-1F2F] Approved REF00000680 DG00263 Mycobacterium infection [ICD-11: 1B10-1B21] Investigative REF00000679 DG00263 Crohn disease [ICD-11: DD70] Approved REF00000679 DG00219 Pneumonia [ICD-11: CA40] Approved REF00000679 DG00065 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Withdrawn from market REF00000676 DG00065 Fungal infection [ICD-11: 1F29-1F2F] Approved REF00000676 DG00221 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000672; REF00000737; REF00001114; REF00002840; REF00002843; REF00002870 DG00264 Endocarditis [ICD-11: BB40-BA42] Approved REF00000666 DG00131 Fungal infection [ICD-11: 1F29-1F2F] Approved REF00000665; REF00002891 DG00445 Bowel habit change [ICD-11: ME05] Approved REF00000663 DG00186 HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] Approved REF00000662; REF00002902 DG00047 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000662; REF00002902 DG00252 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000656 DG00145 Gram-negative bacterial infection [ICD-11: 1B74-1G40] Phase 1 REF00000654; REF00002899 DG00310 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000654; REF00002899 DG00188 Discovery agent [ICD-11: N.A.] Investigative REF00000654; REF00002899 DG00139 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000649; REF00001399 DG00182 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000645; REF00000739; REF00002344; REF00002874; REF00002890 DG00259 Lyme borreliosis [ICD-11: 1C1G] Approved REF00000641 DG00259 Bronchitis [ICD-11: CA20] Approved REF00000641 DG00259 Acne vulgaris [ICD-11: ED80] Approved REF00000641 DG00147 Fungal infection [ICD-11: 1F29-1F2F] Approved REF00000632 DG00251 Acne vulgaris [ICD-11: ED80] Approved REF00000619; REF00002749; REF00002842; REF00002895; REF00002908 DG00038 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000619; REF00002749; REF00002842; REF00002895; REF00002908 DG00237 Gram-positive bacterial infection [ICD-11: 1B74-1F40] Approved REF00000619; REF00002749; REF00002842; REF00002895; REF00002908 DG00313 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000619; REF00002749; REF00002842; REF00002895; REF00002908 DG00127 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000619; REF00002749; REF00002842; REF00002895; REF00002908 DG00271 General pain disorder [ICD-11: 8E43] Approved REF00000618 DG00279 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Approved REF00000610 DG00258 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000608 DG00258 Malaria [ICD-11: 1F45] Investigative REF00000608 DG00004 Urinary tract infection [ICD-11: GC08] Approved REF00000601 DG00302 Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 REF00000599 DG00242 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000593; REF00000748; REF00002853 DG00190 Retinopathy [ICD-11: 9B71] Investigative REF00000580 DG00064 Mycobacterium infection [ICD-11: 1B10-1B21] Approved REF00000580 DG00064 HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] Approved REF00000580 DG00190 HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] Approved REF00000580 DG00173 Urinary tract infection [ICD-11: GC08] Approved REF00000572; REF00002090 DG00173 Prostate disease [ICD-11: GA91] Approved REF00000572; REF00002090 DG00173 Bronchitis [ICD-11: CA20] Approved REF00000572; REF00002090 DG00173 Pancreatic cancer [ICD-11: 2C10] Phase 3 REF00000572; REF00002090 DG00156 Pneumonia [ICD-11: CA40] Phase 3 REF00000540; REF00000570; REF00000800; REF00001475; REF00001615; REF00001744 DG00156 Skin and skin-structure infection [ICD-11: 1F28-1G0Z] Phase 3 REF00000540; REF00000570; REF00000800; REF00001475; REF00001615; REF00001744 DG00207 Respiratory infection [ICD-11: CA07-CA4Z] Approved REF00000540; REF00000570; REF00000800; REF00001475; REF00001615; REF00001744 DG00283 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000540; REF00000570; REF00000800; REF00001475; REF00001615; REF00001744 DG00311 Bacterial infection [ICD-11: 1A00-1C4Z] Approved REF00000540; REF00000570; REF00000800; REF00001475; REF00001615; REF00001744 DG01500 Malaria [ICD-11: 1F45] Discontinued in Phase 1 REF00000491 DG00618 Thyroid cancer [ICD-11: 2D10] Phase 1 REF00003237 DG00618 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00003237 DG00618 Renal cell carcinoma [ICD-11: 2C90] Phase 3 REF00003237 DG00618 Ovarian cancer [ICD-11: 2C73] Phase 2 REF00003237 DG00618 Non-small-cell lung cancer [ICD-11: 2C25] Phase 1 REF00003237 DG00618 Melanoma [ICD-11: 2C30] Phase 2 REF00003237 DG00618 Hepatocellular carcinoma [ICD-11: 2C12] Phase 1 REF00003237 DG00618 Hepatocellular carcinoma [ICD-11: 2C12] Phase 2 REF00003237 DG00722 Trypanosomiasis [ICD-11: 1D51-1F53] Phase 2 REF00003654 DG00722 African trypanosomiasis [ICD-11: 1F51] Approved REF00003654 DG00770 Dizziness [ICD-11: MB48] Phase 1 REF00003754 DG00869 Liver disease [ICD-11: DB90-DB9Z] Approved REF00002964 DG01052 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 REF00003380 DG01090 Type-2 diabetes [ICD-11: 5A11] Approved REF00003829 DG01090 Type-2 diabetes [ICD-11: 5A11] Phase 3 REF00003829 DG01090 Type-2 diabetes [ICD-11: 5A11] Phase 3 REF00003829 DG01090 Peripheral arterial disease [ICD-11: BD4Z] Phase 1 REF00003829 DG01248 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented REF00003318 DG01248 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00003318 DG01248 Non-small cell lung cancer [ICD-11: 2C25] Investigative REF00003318 DG01248 Neuroblastoma [ICD-11: 2A00] Investigative REF00003318 DG01248 Mammary analogue secretory carcinoma [ICD-11: 2C60-2C6Y] Investigative REF00003318 DG01248 Colorectal cancer [ICD-11: 2B91] Approved REF00003318 DG01248 Colorectal cancer [ICD-11: 2B91] Investigative REF00003318 DG01285 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 REF00003586 DG01285 Small-cell lung cancer [ICD-11: 2C25] Phase 2 REF00003586 DG01285 Ovarian cancer [ICD-11: 2C73] Phase 2 REF00003586 DG01285 leukaemia [ICD-11: 2A60-2B33] Phase 1 REF00003586 DG01285 leukaemia [ICD-11: 2A60-2B33] Phase 1 REF00003586 DG01285 Endometrial cancer [ICD-11: 2C76] Phase 2 REF00003586 DG01303 Ventilator-associated pneumonia [ICD-11: PK80-PK81] Phase 2 REF00003034 DG01303 Urinary tract infection [ICD-11: GC08] Phase 4 REF00003034 DG01303 Hospital-acquired pneumonia [ICD-11: CA40] Approved REF00003034 DG01303 Healthcare-associated pneumonia [ICD-11: CA00-CA40] Phase 1 REF00003034 DG01477 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00004478 DG01477 Non-small-cell lung cancer [ICD-11: 2C25] Phase 1 REF00004478 DG01477 Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative REF00004478 DG01498 Discovery agent [ICD-11: N.A.] Terminated REF00004487 DG01501 Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 REF00004196 DG01509 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00004088 DG01513 Metastatic colorectal cancer [ICD-11: 2D85] Phase 2 REF00003968 DG01516 Breast cancer [ICD-11: 2C60] Approved REF00003969 DG01523 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00004033 DG01530 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative REF00003965 DG01539 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00004038 DG01555 Triple negative breast cancer [ICD-11: 2C60-2C6Y] Phase 3 REF00004276 DG01555 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00004276 DG01557 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00004037 DG01562 Obesity [ICD-11: 5B81] Phase 2 REF00003900 DG01565 Thrombosis [ICD-11: DB61-GB90] Approved REF00004551 DG01571 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative REF00004294 DG01571 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00004294 DG01571 Biliary tract cancer [ICD-11: 2C15] Phase 2 REF00004294 DG01572 Lung cancer [ICD-11: 2C25] Phase 3 REF00004520 DG01573 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative REF00004527 DG01575 Myeloproliferative neoplasm [ICD-11: 2A22] Approved REF00004327 DG01575 Breast cancer [ICD-11: 2C60] Phase 1 REF00004327 DG01581 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00004362 DG01581 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00004362 DG01581 Malignant mesothelioma [ICD-11: 2C26] Application submitted REF00004362 DG01583 Rectal adenocarcinoma [ICD-11: 2B92] Investigative REF00003901 DG01583 Nasopharyngeal carcinoma [ICD-11: 2B6B] Phase 2 REF00003901 DG01584 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00003999 DG01590 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00004449 DG01599 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative REF00004377 DG01599 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00004377 DG01616 Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative REF00004194 DG01616 Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative REF00004194 DG01616 Lymphangioleiomyomatosis [ICD-11: CB07] Phase 1/2 REF00004194 DG01620 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00004532 DG01623 Systemic mastocytosis [ICD-11: 2A21] Investigative REF00003968 DG01623 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative REF00003968 DG01623 Glioma [ICD-11: 2A00] Phase 2 REF00003968 DG01623 Gastrointestinal stromal tumour [ICD-11: 2B5B] Approved REF00003968 DG01628 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 REF00004139 DG01637 Discovery agent [ICD-11: N.A.] Approved REF00003917 DG01656 Non-small-cell lung cancer [ICD-11: 2C25] Phase 2 REF00004143 DG01663 Colorectal cancer [ICD-11: 2B91] Phase 2 REF00004397 DG01664 Non-small-cell lung cancer [ICD-11: 2C25] Phase 2 REF00004497 DG01664 Liver cancer [ICD-11: 2C12] Approved REF00004497 DG01814 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00004205 DG01814 Osteosarcoma [ICD-11: 2B51] Phase 2 REF00004205 DG01835 Malaria [ICD-11: 1F45] Approved REF00003895 DG01846 Attention deficit hyperactivity disorder [ICD-11: 6A05] Phase 3 REF00004336 DG01850 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00004554 DG01854 Graves disease [ICD-11: 5A02] Approved REF00004497 DG01854 Diabetic macular edema [ICD-11: 9B71] Investigative REF00004497 DG01857 Multiple myeloma [ICD-11: 2A83] Phase 1 REF00003956 DG01868 Hyperlipidaemia [ICD-11: 5C80] Approved REF00004448 DG01869 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00003948 DG01869 Hepatocellular carcinoma [ICD-11: 2C12] Phase 2 REF00003948 DG01869 Head and neck cancer [ICD-11: 2D42] Phase 2 REF00003948 DG01871 Breast cancer [ICD-11: 2C60] Phase 2 REF00004016 DG01873 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00004191 DG01876 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00004353 DG01877 Haematological malignancy [ICD-11: 2B33] Phase 3 REF00004187 DG01879 Thyroid cancer [ICD-11: 2D10] Phase 3 REF00004300 DG01879 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 REF00004300 DG01879 Non-small-cell lung cancer [ICD-11: 2C25] Phase 2 REF00004300 DG01879 Melanoma [ICD-11: 2C30] Approved REF00004300 DG01883 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative REF00004564 DG01885 Discovery agent [ICD-11: N.A.] Approved REF00003865 DG01892 Squamous head and neck cell carcinom [ICD-11: 2D60] Approved REF00004592 DG01892 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00004592 DG01892 Renal cell carcinoma [ICD-11: 2C90] Phase 1 REF00004592 DG01892 Gastric adenocarcinoma [ICD-11: 2B72] Investigative REF00004592 DG01892 Breast cancer [ICD-11: 2C60] Phase 1 REF00004592 DG01893 Hairy cell leukaemia [ICD-11: 2A82] Phase 2 REF00003922 DG01901 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00004569 DG01902 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00004574 DG01902 Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 REF00004574 DG01902 Haematological malignancy [ICD-11: 2B33] Phase 1 REF00004574 DG01902 Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 REF00004574 DG02034 . . . . DG02001 Bone disease [ICD-11: FC0Z] Phase 2 . DG02009 Discovery agent [ICD-11: N.A.] Investigative . DG02013 Myeloid leukaemia [ICD-11: 2B33] Phase 1 . DG02024 Discovery agent [ICD-11: N.A.] Investigative . DG02031 Schizophrenia [ICD-11: 6A20] Approved . DG02038 Obesity [ICD-11: 5B80-5B81] Approved . DG02035 Systemic sclerosis [ICD-11: 4A42] Phase 3 . DG02020 Type-2 diabetes [ICD-11: 5A11] Terminated . DG02016 . . . . DG02014 Recurrent glioblastoma [ICD-11: 2A00] Phase 2 . DG02019 Heart failure [ICD-11: BD10-BD1Z] Terminated . DG02029 Discovery agent [ICD-11: N.A.] Investigative . DG02002 . . . . DG02030 . . . . DG02036 . . . . DG02003 . . . . DG02007 Small-cell lung cancer [ICD-11: 2C25] Phase 2 . DG02017 Synovial sarcoma [ICD-11: 2B5A] Phase 3 . DG02025 Orthostatic hypotension [ICD-11: BA21] Approved . DG02010 . . . . DG02023 . . . . DG02026 Lymphoma [ICD-11: 2A80-2A86] Phase 4 . DG02039 . . . . DG02028 . . . . DG02008 . . . . DG02021 . . . . DG02037 . . . . DG02015 . . . . DG02004 . . . . DG02005 . . . . DG02006 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 . DG02011 . . . . DG02012 . . . . DG02018 . . . . DG02022 . . . . DG02027 . . . . DG02033 . . . . DG02040 . . . . DG02041 . . . . DG02042 . . . . DG02043 . . . . DG02050 Discovery agent [ICD-11: N.A.] Investigative REF00005440 DG02051 . . . REF00005430 DG02052 Prostate cancer [ICD-11: 2C82] Phase 2 REF00005306 DG02053 Fungal infection [ICD-11: 1F29-1F2F] Approved REF00005238 DG02054 Gastroesophageal reflux disease [ICD-11: DA22] Approved REF00005215 DG02055 . . . REF00005262 DG02056 Discovery agent [ICD-11: N.A.] Investigative REF00005427 DG02057 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved REF00005249 DG02058 Colorectal cancer [ICD-11: 2B91] Phase 2 REF00005233 DG02059 Myelodysplastic syndrome [ICD-11: 2A37] Approved REF00005419 DG02060 . . . REF00005445 DG02061 Peripheral T-cell lymphoma [ICD-11: 2A90] Approved REF00005447 DG02062 . . . REF00005374 DG02063 . . . REF00005362 DG02064 . . . REF00005307 DG02065 Discovery agent [ICD-11: N.A.] Investigative REF00005438 DG02066 leukaemia [ICD-11: 2A60-2B33] Phase 2 REF00005300 DG02067 Myelofibrosis [ICD-11: 2A20] Phase 1 REF00005394 DG02068 Pancreatic cancer [ICD-11: 2C10] Phase 3 REF00005300 DG02069 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 REF00005417 DG02070 Idiopathic pulmonary fibrosis [ICD-11: CB03] Phase 2 REF00005427 DG02071 . . . REF00005209 DG02072 Haematological malignancy [ICD-11: 2B33] Phase 1 REF00005261 DG02073 . . . REF00005217 DG02074 Breast cancer [ICD-11: 2C60-2C6Y] Phase 3 REF00005295 DG02075 Infectious disease [ICD-11: 1A00-CA43] Investigative REF00005297 DG02076 . . . REF00005306 DG02077 Myelofibrosis [ICD-11: 2A20] Phase 2 REF00005287 DG02078 Basal cell carcinoma [ICD-11: 2C32] Phase 2 REF00005434 DG02079 Hepatitis C virus infection [ICD-11: 1E50-1E51] Phase 3 REF00005351 DG02080 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative REF00005392 DG02081 . . . REF00005251 DG02082 . . . REF00005422 DG02083 Acute myelogenous leukaemia [ICD-11: 2A41] Phase 1/2 REF00005417 DG02084 Discovery agent [ICD-11: N.A.] Investigative REF00005394 DG02085 . . . REF00005287 DG02086 . . . REF00005432 DG02087 . . . REF00005442 DG02088 . . . REF00005211 DG02089 Non-small cell lung cancer [ICD-11: 2C25] Phase 3 REF00005236 DG02090 . . . REF00005295 DG02091 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 REF00005380 DG02092 ER-positive breast cancer [ICD-11: 2C60-2C6Y] Phase 2 REF00005295 DG02093 . . . REF00005258 DG02094 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 REF00005392 DG02095 Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 REF00005380 DG02096 Non-small-cell lung cancer [ICD-11: 2C25] Phase 3 REF00005418 DG02097 Non-small-cell lung cancer [ICD-11: 2C25] Phase 3 REF00005255 DG02098 . . . REF00005295 DG02099 . . . REF00005418 DG02100 . . . REF00005444 DG02101 Herpes simplex virus infection [ICD-11: 1F00] Phase 3 REF00005416 DG02102 . . . REF00005295 DG02103 . . . REF00005437 DG02104 . . . REF00005428 DG02105 . . . REF00005295 DG02106 . . . REF00005262 DG02107 . . . REF00005420 DG02108 . . . REF00005421 DG02109 . . . REF00005410 DG02110 . . . REF00005408 DG02111 . . . REF00005423 DG02112 . . . REF00005376 DG02113 . . . REF00005397 DG02114 . . . REF00005424 DG02115 . . . REF00005425 DG02116 . . . REF00005425 DG02117 . . . REF00005241 DG02118 . . . REF00005426 DG02119 . . . REF00005282 DG02120 . . . REF00005386 DG02121 . . . REF00005386 DG02122 . . . REF00005433 DG02123 . . . REF00005433 DG02124 . . . REF00005436 DG02125 . . . REF00005303 DG02126 . . . REF00005446 DG02127 . . . REF00005343 DG02128 . . . REF00005294 DG02129 . . . REF00005404 DG02130 . . . REF00005450 DG02131 . . . REF00005451 DG02132 . . . REF00005352 DG02133 . . . REF00005453 DG02134 . . . REF00005453 DG02135 . . . REF00005325 DG02136 . . . REF00005325 DG02137 . . . REF00005325 DG02138 . . . REF00005325 DG02139 . . . REF00005295 DG02140 . . . REF00005295 DG02141 . . . REF00005295 DG02142 . . . REF00005381 DG02143 . . . REF00005381 DG02144 . . . REF00005226 DG02145 . . . REF00005225 DG02146 . . . REF00005246 DG02147 . . . REF00005246 DG02148 . . . REF00005415 DG02149 . . . REF00005252 DG02150 . . . REF00005252 DG02151 . . . REF00005245 DG02152 . . . REF00005243 DG02153 . . . REF00005427 DG02154 . . . REF00005427 DG02155 . . . REF00005429 DG02156 . . . REF00005429 DG02157 . . . REF00005431 DG02158 . . . REF00005435 DG02159 . . . REF00005435 DG02160 . . . REF00005440 DG02161 . . . REF00005441 DG02162 . . . REF00005443 DG02163 . . . REF00005448 DG02164 . . . REF00005393 DG02165 . . . REF00005393 DG02166 . . . REF00005449 DG02167 . . . REF00005451 DG02168 . . . REF00005452 DG02169 . . . REF00005454 DG02170 . . . REF00005222 DG02171 . . . REF00005439